Archive for the ‘Gene Therapy Research’ Category

DUBLIN--(BUSINESS WIRE)--The "Growth Opportunities in Gene Therapy, Automated Bioanalytics, and Biomarker Platforms" report has been added to ResearchAndMarkets.com's offering.

The research provides technological insights across inflammation, infectious diseases, and microbiomics.

The Life Science, Health & Wellness TOE will feature disruptive technology advances in the global life sciences industry. The technologies and innovations profiled will encompass developments across genetic engineering, drug discovery and development, biomarkers, tissue engineering, synthetic biology, microbiome, disease management, as well as health and wellness among several other platforms.

The Health & Wellness cluster tracks developments in a myriad of areas including genetic engineering, regenerative medicine, drug discovery and development, nanomedicine, nutrition, cosmetic procedures, pain and disease management and therapies, drug delivery, personalized medicine, and smart healthcare.

Innovations in Life Sciences, Health & Wellness from:

For more information about this report visit https://www.researchandmarkets.com/r/tkufmb

Read this article:
2020 Report: Growth Opportunities in Gene Therapy, Automated Bioanalytics, and Biomarker Platforms - ResearchAndMarkets.com - Business Wire

A team of Irish scientists have developed a gene therapy that could potentially lead to a new treatment for an eye disease causing progressive loss of vision, which affects many thousands of people across the globe.

The breakthrough therapy, which offers hope for people with dominant optic atrophy (DOA), was devised by researchers at Trinity College Dublin in collaboration with clinicians at the Royal Victoria Eye and Ear Hospital and the Mater hospital in Dublin.

It also has implications for a much wider suite of neurological disorders associated with ageing which collectively affect millions of people worldwide.

DOA is an inherited disorder characterised by degeneration of optic nerves. It typically starts during the first decade of life. Affected people usually develop moderate visual loss and colour vision defects but severity varies, symptoms can worsen over time and some people become blind. At present, there is no way to prevent or cure DOA.

The scientists published their results in Frontiers in Neuroscience on Thursday.

A gene (OPA1) provides instructions for making a protein found in cells and tissues throughout the body that is pivotal to the proper function of mitochondria, the energy generators in cells.

Without the protein, mitochondrial function is sub-optimal; the normally well-interconnected mitochondrial network in healthy cells becomes highly disrupted. For those with DOA, it is mutations in OPA1 and the dysfunctional mitochondria that are responsible for onset and progression of the disorder.

Led by research fellow Dr Daniel Maloney and Prof Jane Farrar from TCD School of Genetics and Microbiology, the gene therapy successfully protected the visual function of mice who were treated with a chemical targeting the mitochondria and were consequently living with dysfunctional mitochondria.

The scientists also found the gene therapy improved mitochondrial performance in human cells that contained mutations in the OPA1 gene.

We used a clever lab technique that allows scientists to provide a specific gene to cells that need it using specially engineered non-harmful viruses, Dr Maloney said.

This allowed us to directly alter the functioning of the mitochondria in the cells we treated, boosting their ability to produce energy which, in turn, helps protect them from cell damage.

Excitingly, our results demonstrate that this OPA1-based gene therapy can potentially provide benefit for diseases like DOA, which are due to OPA1 mutations, and also possibly for a wider array of diseases involving mitochondrial dysfunction.

Mitochondrial dysfunction causes problems in neurological disorders such as Alzheimers and Parkinsons disease. The impacts gradually build up over time, which is why many may associate such disorders with ageing.

Prof Farrar added: We are very excited by the prospect of this new gene therapy strategy, although it is important to highlight that there is still a long journey to complete from a research and development perspective before this therapeutic approach may one day be available as a treatment.

Because mitochondrial dysfunction was implicated in so many neurological disorders, there was great potential for this type of therapeutic strategy to make a major societal impact, she said.

The research was supported by Science Foundation Ireland, the Health Research Board of Ireland, Fighting Blindness Ireland, and Health Research Charities Ireland.

Original post:
Irish scientists develop gene therapy for inherited vision loss disorder - The Irish Times

Nov. 24, 2020 12:00 UTC

Appoints former Chief Medical Officer of Spark Therapeutics, Kathy Reape, M.D., and Chief Scientific Officer of Intellia Therapeutics, Laura Sepp-Lorenzino, Ph.D., to board of directors

Directors bring significant gene therapy translational and development expertise ahead of GM2 gangliosidosis clinical trial initiation in 2020 and submission of four INDs by the end of 2021

DALLAS--(BUSINESS WIRE)-- Taysha Gene Therapies, Inc. (Nasdaq: TSHA), a patient-centric gene therapy company focused on developing and commercializing AAV-based gene therapies for the treatment of monogenic diseases of the central nervous system in both rare and large patient populations, today announced the appointment of Kathy Reape, M.D., and Laura Sepp-Lorenzino, Ph.D., to the companys board of directors.

Drs. Reape and Sepp-Lorenzino bring significant gene therapy translational and development expertise to our board, said RA Session II, President, Founder and CEO of Taysha Gene Therapies. Their combined gene therapy experience across preclinical and clinical development will be invaluable as we continue to advance our broad portfolio into the clinic. Across all levels of the organization, we are building a team that has the passion, experience and talent to execute on our mission of eradicating monogenic CNS disease.

Dr. Reape was most recently Chief Medical Officer at Spark Therapeutics where she oversaw clinical development, pharmacovigilance and medical affairs activities and was a key member of the team responsible for the development and commercialization of the first FDA-approved in vivo gene therapy, LUXTURNA, for an inherited retinal disease caused by mutations in both copies of the RPE65 gene. She also oversaw the development of Sparks pipeline of gene therapies addressing CNS disease, hemophilia, metabolic disorders and inherited retinal dystrophies. She has over 18 years of experience in the pharmaceutical industry in clinical research and development and has been involved with approximately two dozen product approvals including small molecules, biologics, biosimilars and therapeutic devices. She received both her undergraduate and M.D. degrees from the University of Pennsylvania and completed her internship and residency at the University of Florida and University of Medicine and Dentistry of New Jersey.

Taysha has built a deep pipeline of potentially transformative gene therapies for patients with life-threatening CNS diseases, said Dr. Reape. Many of the conditions that Taysha is addressing have no therapeutic alternatives, are associated with a poor quality of life and often result in a shortened life expectancy. It is important that we rapidly advance these gene therapies into the clinic to serve patients so desperately in need.

Dr. Sepp-Lorenzino is currently the Chief Scientific Officer at Intellia Therapeutics and has held several senior positions over her extensive career. Most recently, she was Vice President and Head of Nucleic Acid Therapies at Vertex Pharmaceuticals. She previously served as Alnylams Vice President and Entrepreneur-in-Residence, where she led the hepatic infectious disease strategies therapeutic area and was a key figure in partnering and in-licensing activities. She spent 14 years at Merck & Co., including as Executive Director and Department Head of the RNA therapeutics discovery biology unit. Dr. Sepp-Lorenzino received her degree in biochemistry at the University of Buenos Aires, Argentina and her M.S. and Ph.D. in biochemistry from New York University.

Joining the Taysha board is a truly exceptional opportunity to contribute to the development of multiple innovative gene therapies, commented Dr. Sepp-Lorenzino. Taysha is taking a leadership position in the industry by combining decades of gene therapy experience with a portfolio of programs that have the potential to address the underlying biology of various CNS disorders in order create an engine for potential new treatments.

About Taysha Gene Therapies

Taysha Gene Therapies (Nasdaq: TSHA) is on a mission to eradicate monogenic CNS disease. With a singular focus on developing curative medicines, we aim to rapidly translate our treatments from bench to bedside. We have combined our teams proven experience in gene therapy drug development and commercialization with the world-class UT Southwestern Gene Therapy Program to build an extensive, AAV gene therapy pipeline focused on both rare and large-market indications. Together, we leverage our fully integrated platforman engine for potential new cureswith a goal of dramatically improving patients lives. More information is available at http://www.tayshagtx.com.

Forward-Looking Statements

This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Words such as anticipates, believes, expects, intends, projects, and future or similar expressions are intended to identify forward-looking statements. Forward-looking statements include statements concerning or implying the conduct or timing of our clinical trials and our research, development and regulatory plans for our product candidates, the potential of our product candidates to positively impact quality of life and alter the course of disease in the patients we seek to treat, our research, development and regulatory plans for our product candidates, the potential for these product candidates to receive regulatory approval from the FDA or equivalent foreign regulatory agencies, and whether, if approved, these product candidates will be successfully distributed and marketed. Forward-looking statements are based on management's current expectations and are subject to various risks and uncertainties that could cause actual results to differ materially and adversely from those expressed or implied by such forward-looking statements. Accordingly, these forward-looking statements do not constitute guarantees of future performance, and you are cautioned not to place undue reliance on these forward-looking statements. Risks regarding our business are described in detail in our Securities and Exchange Commission (SEC) filings, including in our Quarterly Report on Form 10-Q for the quarter ended September 30, 2020, which is available on the SECs website at http://www.sec.gov. Additional information will be made available in other filings that we make from time to time with the SEC. Such risks may be amplified by the impacts of the COVID-19 pandemic. These forward-looking statements speak only as of the date hereof, and we disclaim any obligation to update these statements except as may be required by law.

View source version on businesswire.com: https://www.businesswire.com/news/home/20201124005342/en/

See more here:
Taysha Gene Therapies Adds Industry-Leading Gene Therapy Executives to Board of Directors - BioSpace

AUSTIN, Texas--(BUSINESS WIRE)--Genprex, Inc. (Genprex or the Company) (NASDAQ: GNPX), a clinical-stage gene therapy company focused on developing life-changing therapies for patients with cancer and diabetes, today announced that the Company will participate at the Diamond Equity Research Emerging Growth Invitational taking place virtually on December 1, 2020. Genprexs Executive Vice President and Chief Operating Officer, Michael Redman, will virtually deliver a company overview to investors followed by a guided question and answer session.

Event: Diamond Equity Research Emerging Growth InvitationalDate: Tuesday, December 1Time: 11:40 a.m. ESTRegistration Link: https://bit.ly/2UJS3Si

A live audio webcast and archive of the conference presentation will be available for a period of time using the registration link above. For more information on the Diamond Equity Research Emerging Growth Invitational, please contact your Diamond Equity Research representative.

About Genprex, Inc.

Genprex, Inc. is a clinical-stage gene therapy company focused on developing life-changing therapies for patients with cancer and diabetes. Genprexs technologies are designed to administer disease-fighting genes to provide new therapies for large patient populations with cancer and diabetes who currently have limited treatment options. Genprex works with world-class institutions and collaborators to develop drug candidates to further its pipeline of gene therapies in order to provide novel treatment approaches. The Companys lead product candidate, REQORSA (quaratusugene ozeplasmid), is being evaluated as a treatment for non-small cell lung cancer (NSCLC). REQORSA has a multimodal mechanism of action that has been shown to interrupt cell signaling pathways that cause replication and proliferation of cancer cells; re-establish pathways for apoptosis, or programmed cell death, in cancer cells; and modulate the immune response against cancer cells. REQORSA has also been shown to block mechanisms that create drug resistance. In January 2020, the U.S. Food and Drug Administration granted Fast Track Designation for REQORSA for NSCLC in combination therapy with osimertinib (AstraZenecas Tagrisso) for patients with EFGR mutations whose tumors progressed after treatment with osimertinib alone.

For more information, please visit the Companys web site at http://www.genprex.com or follow Genprex on Twitter, Facebook and LinkedIn.

Forward-Looking Statements

Statements contained in this press release regarding matters that are not historical facts are "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995. Because such statements are subject to risks and uncertainties, actual results may differ materially from those expressed or implied by such forward-looking statements. Such statements include, but are not limited to, statements regarding the effect of Genprexs product candidates, alone and in combination with other therapies, on cancer and diabetes, regarding potential, current and planned clinical trials, regarding the Companys future growth and financial status and regarding our commercial partnerships and intellectual property licenses. Risks that contribute to the uncertain nature of the forward-looking statements include the presence and level of the effect of our product candidates, alone and in combination with other therapies, on cancer; the timing and success of our clinical trials and planned clinical trials of REQORSA immunogene therapy drug, alone and in combination with targeted therapies and/or immunotherapies, and whether our other potential product candidates, including GPX-002, our gene therapy in diabetes, advance into clinical trials; the success of our strategic partnerships, including those relating to manufacturing of our product candidates; the timing and success at all of obtaining FDA approval of REQORSA and our other potential product candidates including whether we receive or benefit from fast track or similar regulatory designations; costs associated with developing our product candidates, whether we identify and succeed in acquiring other technologies and whether patents will ever be issued under patent applications that are the subject of our license agreements or otherwise. These and other risks and uncertainties are described more fully under the caption Risk Factors and elsewhere in our filings and reports with the United States Securities and Exchange Commission. All forward-looking statements contained in this press release speak only as of the date on which they were made. We undertake no obligation to update such statements to reflect events that occur or circumstances that exist after the date on which they were made.

Read the rest here:
Genprex to Participate at the Diamond Equity Research Emerging Growth Invitational on December 1 - Business Wire

"Despite the projected growth in market applications andabundant investment capital, there is a danger that legal andethical concerns related to genetic research could put the brakeson gene editing technologies and product programs emanatingtherefrom."

There are thousands of diseases occurring in humans, animals,and plants caused by aberrant DNA sequences. Traditional smallmolecule and biologic therapies have only had minimal success intreating many of these diseases because they mitigate symptomswhile failing to address the underlying genetic causes. While humanunderstanding of genetic diseases has increased tremendously sincethe mapping of the human genome in the late 1990s, our ability totreat them effectively has been limited by our historical inabilityto alter genetic sequences.

The science of gene editing was born in the 1990s, as scientistsdeveloped tools such as zinc-finger nucleases (ZFNs) and TALEnucleases (TALENs) to study the genome and attempt to altersequences that caused disease. While these systems were anessential first step to demonstrate the potential of gene editing,their development was challenging in practice due to the complexityof engineering protein-DNA interactions.

Then, in 2011, Dr. Emmanuelle Charpentier, a French professor ofmicrobiology, genetics, and biochemistry, and Jennifer Doudna, anAmerican professor of biochemistry, pioneered a revolutionary newgene-editing technology called CRISPR/Cas9. Clustered Regularly InterspacedShort Palindromic Repeats (CRISPR) and Cas9 stands forCRISPR-associated protein 9. In 2020, the revolutionary work ofDrs. Charpentier and Doudna developing CRISPR/Cas9 were recognizedwith the Nobel Prize for Chemistry. The technology was also thesource of a long-running and high-profile patent battle between two groups ofscientsists.

CRISPR/Cas9 for gene editing came about from a naturallyoccurring viral defense mechanism in bacteria. The system ischeaper and easier to use than previous technologies. It deliversthe Cas9 nuclease complexed with a synthetic guide RNA (gRNA) intoa cell, cutting the 'cell's genome at the desired location,allowing existing genes to be removed and new ones added to aliving organism's genome. The technique is essential inbiotechnology and medicine as it provides for the genomes to beedited in vivo with extremely high precision, efficiently, and withcomparative ease. It can create new drugs, agricultural products,and genetically modified organisms or control pathogens and pests.More possibilities include the treatment of inherited geneticdiseases and diseases arising from somatic mutations such ascancer. However, its use in human germline genetic modification ishighly controversial.

The following diagram from CRISPR Therapeutics AG, a Swisscompany, illustrates how it functions:

In the 1990s, nanotechnology and gene editing were necessaryplot points for science fiction films. In 2020, developments likenano-sensors and CRISPR gene editing technology have moved thesetechnologies directly into the mainstream, opening a new frontierof novel market applications. According to The Business ResearchCompany, the global CRISPR technology market reached a value ofnearly $700 million in 2019, is expected to more than double in2020, and reach $6.7 billion by 2030. Market applications targetall forms of life, from animals to plants to humans.

Gene editing's primary market applications are for thetreatment of genetically-defined diseases. CRISPR/Cas9 gene editingpromises to enable the engineering of genomes of cell-basedtherapies and make them safer and available to a broader group ofpatients. Cell therapies have already begun to make a meaningfulimpact on specific diseases, and gene editing helps to acceleratethat progress across diverse disease areas, including oncology anddiabetes.

In the area of human therapy, millions of people worldwidesuffer from genetic conditions. Gene-editing technologies likeCRISPR-Cas9 have introduced a way to address the cause ofdebilitating illnesses like cystic fibrosis and create betterinterventions and therapies. They also have promising marketapplications for agriculture, food safety, supply, anddistribution. For example, grocery retailers are even looking athow gene editing could impact the products they sell. Scientistshave created gene-edited crops like non-browning mushrooms andmildew-resistant grapes - experiments that are part of an effort toprevent spoilage, which could ultimately change the way food issold.

Despite the inability to travel and conduct face-to-facemeetings, attend industry conferences or conduct business otherthan remotely or with social distance, the investment markets forventure, growth, and private equity capital, as well as corporateR&D budgets, have remained buoyant through 2020 to date.Indeed, the third quarter of 2020 was the second strongest quarterever for VC-backed companies, with 88 companies raising roundsworth $100 million or more according to the latest PwC/Moneytreereport. Healthcare startups raised over $8 billion in the quarterin the United States alone. Gene-editing company MammouthBiosciences raised a $45 million round of Series B capital in thesecond quarter of 2020. CRISPR Therapeutics AG raised more in thepublic markets in primary and secondary capital.

Bayer, Humboldt Fund and Leaps are co-leading a $65 million Series A round for Metagenomi, abiotech startup launched by UC Berkeley scientists. Metagenomi,which will be run by Berkeley's Brian Thomas, is developing atoolbox of CRISPR- and non-CRISPR-based gene-editing systems beyondthe Cas9 protein. The goal is to apply machine learning to searchthrough the genomes of these microorganisms, finding new nucleasesthat can be used in gene therapies. Other investors in the Series Ainclude Sozo Ventures, Agent Capital, InCube Ventures and HOFCapital. Given the focus on new therapies and vaccines to treat thenovel coronavirus, we expect continued wind in the sails forgene-editing companies, particularly those with strong productportfolios that leverage the technology.

Despite the projected growth in market applications and abundantinvestment capital, there is a danger that legal and ethicalconcerns related to genetic research could put the brakes ongene-editing technologies and product programs emanating therefrom.The possibility of off-target effects, lack of informed consent forgermline therapy, and other ethical concerns could cause governmentregulators to put a stop on important research and developmentrequired to cure disease and regenerate human health.

Gene-editing companies can only make money by developingproducts that involve editing the human genome. The clinical andcommercial success of these product candidates depends on publicacceptance of gene-editing therapies for the treatment of humandiseases. Public attitudes could be influenced by claims that geneediting is unsafe, unethical, or immoral. Consequently, productscreated through gene editing may not gain the acceptance of thegovernment, the public, or the medical community. Adverse publicreaction to gene therapy, in general, could result in greatergovernment regulation and stricter labeling requirements ofgene-editing products. Stakeholders in government, third-partypayors, the medical community, and private industry must work tocreate standards that are both safe and comply with prevailingethical norms.

The most significant danger to growth in gene-editingtechnologies lies in ethical concerns about their application tohuman embryos or the human germline. In 2016, a group of scientistsedited the genome of human embryos to modify the gene forhemoglobin beta, the gene in which a mutation occurs in patientswith the inherited blood disorder beta thalassemia. Althoughconducted in non-viable embryos, it shocked the public thatscientists could be experimenting with human eggs, sperm, andembryos to alter human life at creation. Then, in 2018, abiophysics researcher in China created the first human geneticallyedited babies, twin girls, causing public outcry (and triggeringgovernment sanctioning of the researcher). In response, the WorldHealth Organization established a committee to advise on thecreation of standards for gene editing oversight and governancestandards on a global basis.

Some influential non-governmental agencies have called for amoratorium on gene editing, particularly as applied to altering thecreation or editing of human life. Other have set forth guidelineson how to use gene-editing technologies in therapeuticapplications. In the United States, the National Institute ofHealth has stated that it will not fund gene-editing studies inhuman embryos. A U.S. statute called "The Dickey-WickerAmendment" prohibits the use of federal funds for researchprojects that would create or destroy human life. Laws in theUnited Kingdom prohibit genetically modified embryos from beingimplanted into women. Still, embryos can be altered in researchlabs under license from the Human Fertilisation and EmbryologyAuthority.

Regulations must keep pace with the change that CRISPR-Cas9 hasbrought to research labs worldwide. Developing international guidelines could be a steptowards establishing cohesive national frameworks. The U.S.National Academy of Sciences recommended seven principles for thegovernance of human genome editing, including promoting well-being,transparency, due care, responsible science, respect for persons,fairness, and transnational co-operation. In the United Kingdom, anon-governmental organization formed in 1991 called The NuffieldCouncil has proposed two principles for the ethical acceptabilityof genome editing in the context of reproduction. First, theintervention intends to secure the welfare of the individual borndue to such technology. Second, social justice and solidarityprinciples are upheld, and the intervention should not result in anintensifying of social divides or marginalizing of disadvantagedgroups in society. In 2016, in application of the same, the CrickInstitute in London was approved to use CRISPR-Cas9 in humanembryos to study early development. In response to a cacophony ofconflicting national frameworks, the International Summit on HumanGene Editing was formed in 2015 by NGOs in the United States, theUnited Kingdom and China, and is working to harmonize regulationsglobal from both the ethical and safety perspectives. As CRISPRco-inventor Jennifer Doudna has written in a now infamous editorialin SCIENCE, "stakeholders must engage in thoughtfullycrafting regulations of the technology without stiflingit."

The COVID-19 pandemic has forced us to rely more on newtechnologies to keep us healthy, adapt to working from home, andmore. The pandemic makes us more reliant on innovative digital,biological, and physical solutions. It has created a united senseof urgency among the public and private industry (together withgovernment and academia) to be more creative about using technologyto regenerate health. With continued advances in computing power, networkarchitecture, communications bandwidths, artificial intelligence,machine learning, and gene editing, society will undoubtedly findmore cures for debilitating disease and succeed in regeneratinghuman health. As science advances, it inevitably intersects withlegal and ethical norms, both for individuals and civil society,and there are new externalities to consider. Legal and ethicalnorms will adapt, rebalancing the interests of each. The fourthindustrial revolution is accelerating, and hopefully towards curingdisease.

Originally published by IPWatchdog.com, November 24,2020.

The content of this article is intended to provide a generalguide to the subject matter. Specialist advice should be soughtabout your specific circumstances.

Here is the original post:
Future Visioning The Role Of CRISPR Gene Editing: Navigating Law And Ethics To Regenerate Health And Cure Disease - Technology - United States -...

Market Study Report, LLC, has recently added a report on the Gene Therapy market which presents substantial inputs about the market size, market share, regional trends, and profit projection of this business sphere. The report also enlightens users regarding the foremost challenges and existing growth tactics implemented by the leading organizations that constitute the dynamic competitive gamut of this industry.

The Gene Therapy market is projected to accomplish a very enviable valuation portfolio by the end of the estimated duration, claims this report. The research study also enumerates that this vertical will register a highly commendable growth rate over the forecast timeframe, while simultaneously elucidating a pivotal overview of this business space. Inclusive of highly significant details pertaining to the overall valuation presently held by this industry, the report also lists down, in meticulous detail, the segmentation of the Gene Therapy market and the growth opportunities prevailing across this vertical.

Request a sample Report of Gene Therapy Market at:https://www.marketstudyreport.com/request-a-sample/2476988?utm_source=cheshire.media&utm_medium=Ram

Enumerating a basic coverage of the Gene Therapy market report:

What pointers are covered in the report with respect to the geographical spectrum of Gene Therapy market?

How meticulously is the Gene Therapy market segmented?

. The report comprises details about the market share that each product holds and the projected valuation of the segment.

. The market share which each application holds alongside the projected valuation that each application will account for is also incorporated in the study.

Ask for Discount on Gene Therapy Market Report at:https://www.marketstudyreport.com/check-for-discount/2476988?utm_source=cheshire.media&utm_medium=Ram

What are the drivers & challenges of the Gene Therapy market?

An analysis of the important competitors in the Gene Therapy market:

The Gene Therapy market report is also comprised of some details such as market concentration ratio, spanning the concentration classes CR3, CR10, and CR5 over the projected timeline.

Enquiry about Gene Therapy market report before Buying at:https://www.marketstudyreport.com/enquiry-before-buying/2476988?utm_source=cheshire.media&utm_medium=Ram

Related Reports:

1. Global Animal Used Parasiticides Market Growth (Status and Outlook) 2020-2025Read More: https://www.marketstudyreport.com/reports/global-animal-used-parasiticides-market-growth-status-and-outlook-2020-2025

2. Global Advanced Wound Care Biologics Market Growth 2020-2025Read More: https://www.marketstudyreport.com/reports/global-advanced-wound-care-biologics-market-growth-2020-2025

Read More Reports On: https://www.marketwatch.com/press-release/direct-to-consumer-genetic-testing-market-analysis-growth-by-top-companies-trends-by-types-and-application-forecast-to-2025-2020-11-26

Contact Us:Corporate Sales,Market Study Report LLCPhone: 1-302-273-0910Toll Free: 1-866-764-2150 Email: [emailprotected]

Read the rest here:
Global Gene Therapy Market Size, Analytical Overview, Growth Factors, Demand, Trends and Forecast to 2025 - Cheshire Media

The Global Gene Therapy Market Research Report Forecast 2020 2024 provides a comprehensive analysis of the market segments, including their dynamics, size, growth, regulatory requirements, competitive landscape, and emerging opportunities of the global industry. It provides an in-depth study of the Gene Therapy market by using SWOT analysis. The research analysts provide an elaborate description of the value chain and its distributor analysis. This Market study provides comprehensive data that enhances the understanding, scope, and application of this report.

The global gene therapy market is expected to reach US$6.42 billion in 2024, witnessing growth at a CAGR of 19.29%, over the period 2020-2024.

(Exclusive Offer: Up to 10% discount on this report)

Get a Sample PDF Copy of the Latest Research on Gene Therapy Market 2020 Before the purchase:

https://www.marketinsightsreports.com/reports/08312273097/global-gene-therapy-market-by-cell-type-vector-type-application-end-user-region-insights-forecast-with-potential-impact-of-covid-19-2020-2024/inquiry?mode=69

Segmentation:

Top Key Players in the Global Gene Therapy Market: Roche Holding AG, Pfizer Inc., Novartis International AG, GlaxoSmithKline PLC, Bristol Myers Squibb Co. (Celgene Corporation) and Gilead Sciences, Inc.

Growth in the gene therapy market has accrued due to the increasing prevalence of chronic diseases, rising healthcare expenditure, expanding urbanization, growth of gene therapy clinical trials and upsurge in economic growth. The market is anticipated to experience certain trends like rapid adoption of personalized medicine, growing occurrence of genetic disorders, advancements in gene therapy and increasing R&D funding. The growth of the market would be challenged by side effects of gene therapy and ethical and safety concerns and high cost of the treatment.

The global gene therapy market has been segmented on the basis of cell type, vector type, application, end-user and region. Depending on the cell type, the market can be bifurcated into somatic cell gene therapy and germ cell gene therapy. According to the vector type, the global gene therapy market can be categorized into retrovirus & gammaretrovirus, adeno-associated viruses (AAV), lentivirus, adenovirus, modified herpes simplex virus and non-viral plasmid vector. Whereas, on the basis of application, the market can be split into oncological disorders, neurological disorders, infectious diseases, cardiovascular diseases, rare diseases and others. Further, in terms of end-user, the global gene therapy market can broadly be segmented into hospitals, specialty treatment centers and other end-users.

The fastest growing regional market is North America due to the rising incidence of cancer and other target diseases, increasing favorable reimbursement scenario in the region and improvements in healthcare infrastructure. Further, the sudden outbreak of COVID-19 is causing an adverse disruption on the overall economy and society, affecting the rate of gene therapy procedures and clinical trials, which is expected to negatively impact the growth of the global gene therapy market during the forecasted period.

Scope of the report:

The report provides a comprehensive analysis of the global gene therapy market segmented on the basis of cell type, vector type, application, end-user and region. The major regional and country markets (North America, Europe, Asia Pacific and Rest of the World) have been analyzed. The market dynamics such as growth drivers, market trends and challenges are analyzed in-depth. The competitive landscape of the market, along with the company profiles of leading players (Roche Holding AG, Pfizer Inc., Novartis International AG, GlaxoSmithKline PLC, Bristol Myers Squibb Co. (Celgene Corporation) and Gilead Sciences, Inc.) are also presented in detail.

Regional Analysis for Market:

For a comprehensive understanding of market dynamics, the global Gene Therapy market is analyzed across key geographies namely: United States, China, Europe, Japan, South-east Asia, India, and others. Each of these regions is analyzed on the basis of market findings across major countries in these regions for a macro-level understanding of the market.

This Gene Therapy Market statistical surveying report underlines the leading merchants in this market everywhere throughout the world. This sector of the report includes market depictions, requirements, and product portrayals, manufacture, competence, contact figures, cost, and revenue. In a comparable way, automated gathering, upstream raw materials, and downstream demand studies are administered.

Browse Complete Report details with Table of Content:

https://www.marketinsightsreports.com/reports/08312273097/global-gene-therapy-market-by-cell-type-vector-type-application-end-user-region-insights-forecast-with-potential-impact-of-covid-19-2020-2024?mode=69

Table Of Content:

Overview: This segment offers an overview of the report to provide an idea regarding the contents and nature of the research report along with a wide synopsis of the global Gene Therapy Market.

Analysis of Leading Players Strategies: Market top players can utilize this analysis to increase the upper hand over their rivals in the market.

Study on Major Market Trends: This segment of the report delivers a broad analysis of the most recent and future market trends.

Forecasts of the Market: The report gives production, consumption, sales, and other market forecasts. Report Buyers will approach exact and approved evaluations of the total market size in terms of value and volume.

Analysis of Regional Growth: This report covered all major regions and countries. The regional analysis will assist market players to formulate strategies specific to target regions, tap into unexplained regional markets, and compare the growth of all regional markets.

The research includes historic data from 2015 to 2020 and forecasts until 2024 which makes the reports an invaluable resource for industry executives, marketing, sales, and product managers, consultants, analysts, and other people looking for key industry data in readily accessible documents with clearly presented tables and graphs.

Buy Full Report:

https://www.marketinsightsreports.com/report/purchase/08312273097?mode=su?mode=69

Customization of this Report:This report can be customized as per your needs for additional data up to 3 companies or countries or 40 analyst hours.

Please contact our sales professional ([emailprotected]), we will ensure you obtain the report which works for your needs.

Note: All the reports that we list have been tracking the impact of COVID-19 on the market. Both upstream and downstream of the entire supply chain has been accounted for while doing this. Also, where possible, we will provide an additional COVID-19 update supplement/report to the report in Q3, please check for with the sales team.

ABOUT US:

Market Insights Reports provides syndicated market research on industry verticals including Healthcare, Information and Communication Technology (ICT), Technology and Media, Chemicals, Materials, Energy, Heavy Industry, etc. Market Insights Reports provides global and regional market intelligence coverage, a 360-degree market view which includes statistical forecasts, competitive landscape, detailed segmentation, key trends, and strategic recommendations.

Contact Us:

Irfan Tamboli (Head of Sales) Market Insights Reports

Phone: + 1704 266 3234 | +91-750-707-8687

Email:[emailprotected] |[emailprotected]

More:
Gene Therapy Market Insights and Global Research and Clinical Survey Report 2020-2024 - The Market Feed

The latest report published by Polaris Market Research, titled Global Gene Therapy Market provides key information about the current status and prospects of the market. The report focuses on the market size, share, growth, emerging trends, and regional analysis of the market. The study also includes a comprehensive analysis of the various market factors, including market drivers, restraints, trends, risk, and opportunities prevailing within the market.

The report provides an in-depth analysis of the global Gene Therapy market that could help market players to devise their strategies and leads to the profitability of their business. The study also profiles key companies present in the market along with their market shares, growth rate, and product launches. The rapidly changing market scenario covering the initial and future assessment of the impact is covered in the report. Further, the report provides niche insights for every possible segment to help market players in the strategic decision-making process and market size estimation of the global Gene Therapy market on a regional and global basis.

Get a Sample Copy of the Report: https://www.polarismarketresearch.com/industry-analysis/gene-therapy-market/request-for-sample

The report produced by Polaris Market Research is widely known for its accuracy as it consists of precise graphs, tables, and figures that give a clear picture of the developments of the products and their market performance in the past and predicts the future trend. It uses statistical surveying for SWOT analysis, PESTLE analysis, predictive analysis, and real-time analysis.

Manufacturers covered in this report are:

Novartis Pharmaceuticals Corporation, Kite Pharma, Incorporated, Spark Therapeutics, Inc, GlaxoSmithKline, Adaptimmune, Bluebird bio

*Note: Additional companies can be included on request

Geographical Overview

The report provides an extensive analysis of the key geographical regions of the market. The regional analysis focused on North America, Latin America, Europe, Asia-Pacific, and Middle East & Africa regions. The report offers insightful information such as demand and supply, production and consumption ratio, import and export, and demand trends in each region. The report also includes covers a country-specific analysis of the each segment and sub-segment of the Gene Therapy market.

Impact of COVID-19

The report also takes into account the impact of the ongoing global crisis of the COVID-19 pandemic, on the global Gene Therapy market. It covers the key information current status of the industries and predicts the post-COVID-19 impact on the global market. The report also sheds light on the financial impact on businesses at the domestic level as well as global level. Polaris Market Research has gathered insights from various industry delegates and has been involved in primary and secondary research to provide customers with data and strategies to address market challenges during COVID-19 and post the COVID-19 pandemic.

Key questions answered in the report

The global Gene Therapy market report will help clients to gain an in-depth understanding of the global Gene Therapy market. The report identifies the ongoing market trend and anticipated growth in the near future to help industry vendors, manufacturers, consultants, and suppliers to align their market-centric strategies. The analytical studies are conducted to identify ensure customer requirements with a thorough understanding of the market capacities.

If you have any special requirements, please let us know and we will offer you the report as you want. Speak to Analyst to know more @ https://www.polarismarketresearch.com/industry-analysis/gene-therapy-market/speak-to-analyst

About Polaris Market Research

Polaris Market Research is a global market research and consulting company. We provide unmatched quality of offerings to our clients present globally. The company specializes in providing exceptional market intelligence and in-depth business research services for our clientele spread across different enterprises.

Contact Us

Corporate Sales, USA

Polaris Market Research

Phone: 1-646-568-9980

Email: [emailprotected]

Web: http://www.polarismarketresearch.com

See the rest here:
Gene Therapy Market Potential Growth, Share and Demand-Analysis of Key Players- Research Forecasts - Cheshire Media

Bridging the gap: SYNGAP1 protein is located mostly at synapses, the junctions between neurons (green). Editors Note

This article was originally published on 24 November, based on preliminary data presented at a conference. We have updated the article to provide additional context.

Spectrum is covering the 2020 International SYNGAP1 Scientific Conference, which took place virtually because of the coronavirus pandemic. Here were highlighting researchers reactions to noteworthy presentations.

Drug test: A new assay allows researchers to test thousands of candidate drugs for their ability to boost expression of the autism gene SYNGAP1. The tool may help researchers identify and screen potential treatments for people with mutations that silence the gene. Gavin Rumbaugh, professor of neuroscience at Scripps Research in Jupiter, Florida, presented the unpublished results on 18 November.

The assay uses neurons from mice with one intact and one mutated copy of SYNGAP1. The researchers genetically engineer the mice so that SYNGAP1 protein made from the intact copy is tagged with luciferase the enzyme that gives fireflies their glow.

They then grow these neurons in tiny wells and add a different candidate drug to each well. The amount of SYNGAP1 protein in the dish gives a proportionate amount of light in your well, Rumbaugh says.

Rumbaugh and his team plan to use the platform to run through more than 100,000 different experimental compounds in 2021, he says.

Thats going to be really exciting for drug discovery efforts for SYNGAP1. I think thats going to be a game changer, says Karun Singh, senior scientist at the University Health Network in Toronto, Canada, who was not involved in the work.

It will be very exciting to see if they are able to uncover any useful hits with their novel approach, says Helen Bateup, associate professor of neurobiology at the University of California, Berkeley, who was not involved in the work.

Treatment across ages: A leading theory of autism is that the condition is characterized by a signaling imbalance: too much excitation or too little inhibition in the brain. One of the key players in creating this imbalance is thought to be inhibitory interneurons, which employ the neurotransmitter gamma-aminobutyric acid (GABA). And mutations to SYNGAP1 may disrupt GABAs function, said James Clement, assistant professor of neuroscience at the Jawaharlal Nehru Centre for Advanced Scientific Research in Bangalore, India, in a presentation on 18 November.

GABA is excitatory early on in brain development and inhibitory later on a switch that seems to be impaired in mice with SYNGAP1 mutations, he says. He and his team have tested a new compound that restores the GABA switch in mice and eases almost all SYNGAP1-related traits including seizures, learning issues and motor impairment in the mice. It works in newborn and adolescent mice. Due to a pending patent application, Clement and his lab are not revealing the compounds name.

I think its important to test efficacy at multiple ages, as they have done, to understand which phenotypes or problems can be improved with early treatment and which might still be responsive to treatment even if its administered later in life, says Bateup, who was not involved in the work. The idea that GABA may remain depolarizing for longer in SYNGAP1 mutant mice is quite interesting.

Clements lab was the only other lab that was presenting at this meeting that presented data from a very early age, says Shilpa Kadam, associate professor of neurology at the Kennedy Krieger Institute in Baltimore, Maryland, who was not involved in the work. Kadam also presented results on mice with SYNGAP1 mutations, showing that from an early age, theseanimalshave seizures thatcan be treated by blocking one type of GABA receptor.

Motor coordination: For mice, the loss of SYNGAP1 function in the striatum impairs their goal-directed learning and seems to lead to inflexible behavior, Bateup said in a presentation on 18 November.

Helen Bateups work looking at striatal function as it relates to motor coordination and motor learning is also pretty exciting and may shed light not only on the motor-coordination difficulties but also the repetitive or habitual motor behaviors, says Constance Smith-Hicks, child neurologist and research scientist at the Kennedy Krieger Institute, who was not involved in the work.

Bateups presentation also demonstrated that SYNGAP1 deletion seems to affect neurons differently depending on which type of dopamine receptor they express.

We know SYNGAP1 is at most excitatory synapses, so why shes seeing some functional effects in one type of cell and not the other, I find that interesting, says Richard Huganir, professor of neuroscience and psychological and brain sciences at Johns Hopkins University in Baltimore, Maryland, who was not involved in the work.

Its exciting to be able to kind of pinpoint which pathway might be involved and get a better understanding of the circuits that are disrupted, says Singh, who was not involved in the work.

Protein levels: People with a nonfunctional copy of SYNGAP1 have about half the typical amount of SYNGAP1 protein. Increasing the activity of the intact copy of the gene could help restore typical functioning, Huganir said in a presentation on 18 November.

He and his team tested this idea on two unique mouse models in unpublished work. Instead ofhaving one intact and one missing copyof the SYNGAP1 gene, as is typical for SYNGAP1 mouse models, each mouse model carriesone intact copy of the gene and one with a mutation seen in people. Both mice produce about half the typical amount of SYNGAP1 protein and show the same behaviors as the classical knockout mouse, despite having different types of mutations.

These new mouse models are crucial because they can directly correlate to what is happening in the humans, says Clement, who was not involved in the work.

Huganir and his team are testing different types of gene therapies to increase SYNGAP1 protein up to the typical levels, and have found that there are two SYNGAP1 protein isoforms, or slight variations of the protein.

One of the isoforms can restore synaptic plasticity in the animal model for SYNGAP1, so I think thats really exciting because even though theres multiple isoforms, it seems that one might be more important from a gene therapy point of view, says Singh, who was not involved in the work. Its pretty exciting to have a specific target now.

Read more reports from the2020 International SYNGAP1 Scientific Conference.

Continue reading here:
Reactions from the 2020 SYNGAP1 Scientific Conference - Spectrum

New York, Nov. 25, 2020 (GLOBE NEWSWIRE) -- Reportlinker.com announces the release of the report "North America Cell Therapy Instruments Market Forecast to 2027 - COVID-19 Impact and Regional Analysis By Product ; Cell Type ; Process ; End User, and Country" - https://www.reportlinker.com/p05989572/?utm_source=GNW

The surge in the number of cell therapy transplantation procedures, growing research and development activities, and rising investments in building production facilities for cell and gene therapy products drive the growth of the North America cell therapy instruments market. However, the low success rate of cell therapies and the high cost of cell-based research is expected to restrain the market growth during the forecast period.

Cell therapy typically involves the administration of somatic cell preparations by injecting or grafting it into the patients body for the treatment of diseases or traumatic damages.The procedure is used to cure diabetes, neurological disorders, related injuries, several cancer types, bones and joints, and genetic disorders.

Continuous research and development activities have led to unique cell therapeutic instruments for the improvement of immune system and efficient treatment of genetic disorders. Various market players provide several consumables such as reagent kits and enzymes as well as devices, equipment, and software to perform various cell therapy processes.

The cell therapy products are derived from animals or human cells and thus need to be protected from contamination.The instruments used in cell therapies help provide protection against contamination and allow scaling up of transplantation.

Companies such as Hitachi Chemical Advanced Therapeutics Solutions; Corning Incorporated; Thermo Fisher Scientific Inc.; Miltenyi Biotec, LLC; Invetech, and Cytiva (General Electric Company) have introduced various equipment and consumables for the cell therapy procedures.

In North America, various healthcare research centers are focused specifically on COVID 19 therapeutics.During the initial phase of COVID-19 crisis, the demand for cell therapy instruments was disrupted owing to change in customer behaviors due to lockdown and supply chain disruptions.

However, the lack of definitive therapy offers significant opportunities for cell therapy instrumentation market players as US FDA has recently approved use of plasma therapy for critically ill COVID 19 patients. Further, the cell therapy instruments market also has significant growth prospects during the post-pandemic period.

On the basis of product, the North America cell therapy instruments market is further segmented into consumables, software, equipment, and systems.The consumables segment held the largest share of the market in 2019 and is expected to register the highest CAGR during the forecast period.

The cell therapy instruments market, based on cell type, is segmented into animal cells and human cells. The human cells segment held a larger share of the market in 2019 and is estimated to register a higher CAGR during 20202027.

On the basis of process, the North America cell therapy instruments market is segmented into cell processing; cell preservation, distribution, and handling; and process monitoring and quality control.The cell processing segment held the largest share of the market in 2019 and is estimated to register the highest CAGR during the forecast period.

The North America cell therapy instruments market, based on end user, is segmented into life science research companies, research institutes, and other end users. The life science research companies segment grasped the greatest share of the market in 2019 and is anticipated to register the highest CAGR from 2020 to 2027.

A few of the major primary and secondary sources associated with this report on the North America cell therapy instruments market are National Center for Biotechnology Information (NCBI); World Health Organization (WHO); American Society of Gene & Cell Therapy (ASGCT); and Global Institute of Stem Cell Therapy and Research (GIOSTAR).Read the full report: https://www.reportlinker.com/p05989572/?utm_source=GNW

About ReportlinkerReportLinker is an award-winning market research solution. Reportlinker finds and organizes the latest industry data so you get all the market research you need - instantly, in one place.

__________________________

Visit link:
North America Cell Therapy Instruments Market Forecast to 2027 - COVID-19 Impact and Regional Analysis By Product ; Cell Type ; Process ; End User,...

The report provides revenue of the global Gene Therapy in Oncology market for the period 20162026, considering 2019 as the base year and 2026 as the forecast year. The report also provides the compound annual growth rate (CAGR) for the global market during the forecast period. The global Gene Therapy in Oncology market studies past as well as current growth trends and opportunities to gain valuable insights of these indicators of the market during the forecast period from 2020 to 2026.

With the advancement in technology, the gene therapy market has transformed during the recent few years. Cancer gene therapy is a technique used for the treatment of cancer where therapeutic DNA is being introduced into the gene of the patient with cancer.

Due to the high success rate during the preclinical and clinical trial, cancer gene therapy is gaining popularity. There are many techniques used for cancer gene therapy, for example, a procedure where the mutated gene is being replaced with a healthy gene or inactivation of gene whose function is abnormal. Recently, a new technique has been developed, where new genes are introduced into the body to help fight against cancer cells.

The study offers a comprehensive analysis on diverse features, including production capacities, demand, product developments, revenue generation, and sales in the Gene Therapy in Oncology market across the globe.

Request Coronavirus Impact Analysis on This [emailprotected] https://www.qyresearchmedical.com/sample/57077

A comprehensive estimate on the Gene Therapy in Oncology market has been provided through an optimistic scenario as well as a conservative scenario, taking into account the sales of Gene Therapy in Oncology during the forecast period. Price point comparison by region with global average price is also considered in the study.

It is pertinent to consider that in a volatile global economy, we havent just conducted Gene Therapy in Oncology market forecasts in terms of CAGR, but also studied the market based on key parameters, including Year-on-Year (Y-o-Y) growth, to comprehend the certainty of the market and to find and present the lucrative opportunities in market.

Download Full Report https://www.qyresearchmedical.com/report/checkout/57077/3500

Drivers and Restraints

This section covers the various factors driving the global Advanced Driver Assistance Systems (ADAS) market. To understand the growth of the market it is important to analyze the various drivers present the market. It provides data by value and volume of different regions and their respective manufacturers. This data will elaborate on the market share occupied by them, predict their revenue concerning strategies, and how they will grow in the future. After explaining the drivers, the report further evaluates the new opportunities and current trends in the market.

Market restraints are factors hampering market growth. Studying these factors is equally pivotal as they help a reader need understand the weaknesses of the market.

Market Segmentation:

The report is divided into major categories comprising product, application, regions and others. Every segment is further sub-segmented into several sub-segmented that are deeply analyzed by experts to offer valuable information to the buyers and market players. Every segment is studied thoroughly in order to offer a better picture to the buyers and stakeholders to benefit from. Information like highest prevailing product, highly demanded product by the application segment and end users are rightly mentioned in the Gene Therapy in Oncology report.

The report includes an elaborate executive summary, along with a snapshot of the growth behavior of various segments included in the scope of the study. Furthermore, the report sheds light on the changing competitive dynamics in the global Gene Therapy in Oncology market. These indices serve as valuable tools for existing market players as well as for entities interested in entering the global Gene Therapy in Oncology market.

Gene Therapy in Oncology Breakdown Data by TypeEx VivoIn VivoGene Therapy in Oncology Breakdown Data by ApplicationHospitalsDiagnostics CentersResearch Institutes

In this study, the years considered to estimate the market size of Gene Therapy in Oncology are as follows:

Major Players Covered in this Report

The updated market research report on Gene Therapy in Oncology market allows the buyers and manufacturers to stay updated with the current market trends, ongoing happenings, and a clear picture on the market scenario. List of key players included in the research report will help the market vendors to know their market position and plan more operational strategies to gain topmost position among other players. The report offers crucial company information on each market player, such as company profile, financial information, and recently adopted growth strategies. This will help other existing players and the new entrants to plan strategies and establish their presence in the market.

Major manufacturers & their revenues, percentage splits, market shares, growth rates and breakdowns of the product markets are determined through secondary sources and verified through the primary sources.

Bristol-Myers SquibbCold GenesysAdvantageneAmgenAstraZenecaBio-Path HoldingsCRISPR TherapeuticsEditas MedicineGeron CorpIdera PharmaceuticalsIntellia TherapeuticsJohnson & JohnsonMarsala BiotechMerckMologen AGOncolytics BiotechOncosecOncotelicShenzhen SiBiono GeneTechSillajen BiotherapeuticsTocagenUniQureZiopharm Oncology

Regional Insights:

The Gene Therapy in Oncology market is segmented as North America, South America, Europe, Asia Pacific, and Middle East and Africa. Researchers have thoroughly studied about the historical market. With extensive research, experts have offered details on the current and the forecast demand made by these regions. The Gene Therapy in Oncology report also includes highlights on the prevailing product demanded by end users and end customers for better understanding of product demand by producers. This will help the producers and the marketing executives to plan their production quantity and plan effective marketing strategies to more buyers. Businesses can hence, increase their product portfolio and expand their global presence. Gene Therapy in Oncology market research report further offers information on the unexplored areas in these regions to help the producers to plan promotional strategies and create demand for their new and updated products. This will again help the manufacturers to increase their customers and emerge as leaders in the near future.

TABLE OF CONTENT

1 Report Overview1.1 Study Scope1.2 Key Market Segments1.3 Players Covered: Ranking by Gene Therapy in Oncology Revenue1.4 Market Analysis by Type1.4.1 Global Gene Therapy in Oncology Market Size Growth Rate by Type: 2020 VS 20261.4.2 Ex Vivo1.4.3 In Vivo1.5 Market by Application1.5.1 Global Gene Therapy in Oncology Market Share by Application: 2020 VS 20261.5.2 Hospitals1.5.3 Diagnostics Centers1.5.4 Research Institutes1.6 Coronavirus Disease 2019 (Covid-19): Gene Therapy in Oncology Industry Impact1.6.1 How the Covid-19 is Affecting the Gene Therapy in Oncology Industry1.6.1.1 Gene Therapy in Oncology Business Impact Assessment Covid-191.6.1.2 Supply Chain Challenges1.6.1.3 COVID-19s Impact On Crude Oil and Refined Products1.6.2 Market Trends and Gene Therapy in Oncology Potential Opportunities in the COVID-19 Landscape1.6.3 Measures / Proposal against Covid-191.6.3.1 Government Measures to Combat Covid-19 Impact1.6.3.2 Proposal for Gene Therapy in Oncology Players to Combat Covid-19 Impact1.7 Study Objectives1.8 Years Considered

2 Global Growth Trends by Regions2.1 Gene Therapy in Oncology Market Perspective (2015-2026)2.2 Gene Therapy in Oncology Growth Trends by Regions2.2.1 Gene Therapy in Oncology Market Size by Regions: 2015 VS 2020 VS 20262.2.2 Gene Therapy in Oncology Historic Market Share by Regions (2015-2020)2.2.3 Gene Therapy in Oncology Forecasted Market Size by Regions (2021-2026)2.3 Industry Trends and Growth Strategy2.3.1 Market Top Trends2.3.2 Market Drivers2.3.3 Market Challenges2.3.4 Porters Five Forces Analysis2.3.5 Gene Therapy in Oncology Market Growth Strategy2.3.6 Primary Interviews with Key Gene Therapy in Oncology Players (Opinion Leaders)

3 Competition Landscape by Key Players3.1 Global Top Gene Therapy in Oncology Players by Market Size3.1.1 Global Top Gene Therapy in Oncology Players by Revenue (2015-2020)3.1.2 Global Gene Therapy in Oncology Revenue Market Share by Players (2015-2020)3.1.3 Global Gene Therapy in Oncology Market Share by Company Type (Tier 1, Tier 2 and Tier 3)3.2 Global Gene Therapy in Oncology Market Concentration Ratio3.2.1 Global Gene Therapy in Oncology Market Concentration Ratio (CR5 and HHI)3.2.2 Global Top 10 and Top 5 Companies by Gene Therapy in Oncology Revenue in 20193.3 Gene Therapy in Oncology Key Players Head office and Area Served3.4 Key Players Gene Therapy in Oncology Product Solution and Service3.5 Date of Enter into Gene Therapy in Oncology Market3.6 Mergers & Acquisitions, Expansion Plans

4 Breakdown Data by Type (2015-2026)4.1 Global Gene Therapy in Oncology Historic Market Size by Type (2015-2020)4.2 Global Gene Therapy in Oncology Forecasted Market Size by Type (2021-2026)

5 Gene Therapy in Oncology Breakdown Data by Application (2015-2026)5.1 Global Gene Therapy in Oncology Market Size by Application (2015-2020)5.2 Global Gene Therapy in Oncology Forecasted Market Size by Application (2021-2026)

6 North America6.1 North America Gene Therapy in Oncology Market Size (2015-2020)6.2 Gene Therapy in Oncology Key Players in North America (2019-2020)6.3 North America Gene Therapy in Oncology Market Size by Type (2015-2020)6.4 North America Gene Therapy in Oncology Market Size by Application (2015-2020)

7 Europe7.1 Europe Gene Therapy in Oncology Market Size (2015-2020)7.2 Gene Therapy in Oncology Key Players in Europe (2019-2020)7.3 Europe Gene Therapy in Oncology Market Size by Type (2015-2020)7.4 Europe Gene Therapy in Oncology Market Size by Application (2015-2020)

8 China8.1 China Gene Therapy in Oncology Market Size (2015-2020)8.2 Gene Therapy in Oncology Key Players in China (2019-2020)8.3 China Gene Therapy in Oncology Market Size by Type (2015-2020)8.4 China Gene Therapy in Oncology Market Size by Application (2015-2020)

9 Japan9.1 Japan Gene Therapy in Oncology Market Size (2015-2020)9.2 Gene Therapy in Oncology Key Players in Japan (2019-2020)9.3 Japan Gene Therapy in Oncology Market Size by Type (2015-2020)9.4 Japan Gene Therapy in Oncology Market Size by Application (2015-2020)

10 Southeast Asia10.1 Southeast Asia Gene Therapy in Oncology Market Size (2015-2020)10.2 Gene Therapy in Oncology Key Players in Southeast Asia (2019-2020)10.3 Southeast Asia Gene Therapy in Oncology Market Size by Type (2015-2020)10.4 Southeast Asia Gene Therapy in Oncology Market Size by Application (2015-2020)

11 India11.1 India Gene Therapy in Oncology Market Size (2015-2020)11.2 Gene Therapy in Oncology Key Players in India (2019-2020)11.3 India Gene Therapy in Oncology Market Size by Type (2015-2020)11.4 India Gene Therapy in Oncology Market Size by Application (2015-2020)

12 Central & South America12.1 Central & South America Gene Therapy in Oncology Market Size (2015-2020)12.2 Gene Therapy in Oncology Key Players in Central & South America (2019-2020)12.3 Central & South America Gene Therapy in Oncology Market Size by Type (2015-2020)12.4 Central & South America Gene Therapy in Oncology Market Size by Application (2015-2020)

13 Key Players Profiles13.1 Bristol-Myers Squibb13.1.1 Bristol-Myers Squibb Company Details13.1.2 Bristol-Myers Squibb Business Overview and Its Total Revenue13.1.3 Bristol-Myers Squibb Gene Therapy in Oncology Introduction13.1.4 Bristol-Myers Squibb Revenue in Gene Therapy in Oncology Business (2015-2020))13.1.5 Bristol-Myers Squibb Recent Development13.2 Cold Genesys13.2.1 Cold Genesys Company Details13.2.2 Cold Genesys Business Overview and Its Total Revenue13.2.3 Cold Genesys Gene Therapy in Oncology Introduction13.2.4 Cold Genesys Revenue in Gene Therapy in Oncology Business (2015-2020)13.2.5 Cold Genesys Recent Development13.3 Advantagene13.3.1 Advantagene Company Details13.3.2 Advantagene Business Overview and Its Total Revenue13.3.3 Advantagene Gene Therapy in Oncology Introduction13.3.4 Advantagene Revenue in Gene Therapy in Oncology Business (2015-2020)13.3.5 Advantagene Recent Development13.4 Amgen13.4.1 Amgen Company Details13.4.2 Amgen Business Overview and Its Total Revenue13.4.3 Amgen Gene Therapy in Oncology Introduction13.4.4 Amgen Revenue in Gene Therapy in Oncology Business (2015-2020)13.4.5 Amgen Recent Development13.5 AstraZeneca13.5.1 AstraZeneca Company Details13.5.2 AstraZeneca Business Overview and Its Total Revenue13.5.3 AstraZeneca Gene Therapy in Oncology Introduction13.5.4 AstraZeneca Revenue in Gene Therapy in Oncology Business (2015-2020)13.5.5 AstraZeneca Recent Development13.6 Bio-Path Holdings13.6.1 Bio-Path Holdings Company Details13.6.2 Bio-Path Holdings Business Overview and Its Total Revenue13.6.3 Bio-Path Holdings Gene Therapy in Oncology Introduction13.6.4 Bio-Path Holdings Revenue in Gene Therapy in Oncology Business (2015-2020)13.6.5 Bio-Path Holdings Recent Development13.7 CRISPR Therapeutics13.7.1 CRISPR Therapeutics Company Details13.7.2 CRISPR Therapeutics Business Overview and Its Total Revenue13.7.3 CRISPR Therapeutics Gene Therapy in Oncology Introduction13.7.4 CRISPR Therapeutics Revenue in Gene Therapy in Oncology Business (2015-2020)13.7.5 CRISPR Therapeutics Recent Development13.8 Editas Medicine13.8.1 Editas Medicine Company Details13.8.2 Editas Medicine Business Overview and Its Total Revenue13.8.3 Editas Medicine Gene Therapy in Oncology Introduction13.8.4 Editas Medicine Revenue in Gene Therapy in Oncology Business (2015-2020)13.8.5 Editas Medicine Recent Development13.9 Geron Corp13.9.1 Geron Corp Company Details13.9.2 Geron Corp Business Overview and Its Total Revenue13.9.3 Geron Corp Gene Therapy in Oncology Introduction13.9.4 Geron Corp Revenue in Gene Therapy in Oncology Business (2015-2020)13.9.5 Geron Corp Recent Development13.10 Idera Pharmaceuticals13.10.1 Idera Pharmaceuticals Company Details13.10.2 Idera Pharmaceuticals Business Overview and Its Total Revenue13.10.3 Idera Pharmaceuticals Gene Therapy in Oncology Introduction13.10.4 Idera Pharmaceuticals Revenue in Gene Therapy in Oncology Business (2015-2020)13.10.5 Idera Pharmaceuticals Recent Development13.11 Intellia Therapeutics10.11.1 Intellia Therapeutics Company Details10.11.2 Intellia Therapeutics Business Overview and Its Total Revenue10.11.3 Intellia Therapeutics Gene Therapy in Oncology Introduction10.11.4 Intellia Therapeutics Revenue in Gene Therapy in Oncology Business (2015-2020)10.11.5 Intellia Therapeutics Recent Development13.12 Johnson & Johnson10.12.1 Johnson & Johnson Company Details10.12.2 Johnson & Johnson Business Overview and Its Total Revenue10.12.3 Johnson & Johnson Gene Therapy in Oncology Introduction10.12.4 Johnson & Johnson Revenue in Gene Therapy in Oncology Business (2015-2020)10.12.5 Johnson & Johnson Recent Development13.13 Marsala Biotech10.13.1 Marsala Biotech Company Details10.13.2 Marsala Biotech Business Overview and Its Total Revenue10.13.3 Marsala Biotech Gene Therapy in Oncology Introduction10.13.4 Marsala Biotech Revenue in Gene Therapy in Oncology Business (2015-2020)10.13.5 Marsala Biotech Recent Development13.14 Merck10.14.1 Merck Company Details10.14.2 Merck Business Overview and Its Total Revenue10.14.3 Merck Gene Therapy in Oncology Introduction10.14.4 Merck Revenue in Gene Therapy in Oncology Business (2015-2020)10.14.5 Merck Recent Development13.15 Mologen AG10.15.1 Mologen AG Company Details10.15.2 Mologen AG Business Overview and Its Total Revenue10.15.3 Mologen AG Gene Therapy in Oncology Introduction10.15.4 Mologen AG Revenue in Gene Therapy in Oncology Business (2015-2020)10.15.5 Mologen AG Recent Development13.16 Oncolytics Biotech10.16.1 Oncolytics Biotech Company Details10.16.2 Oncolytics Biotech Business Overview and Its Total Revenue10.16.3 Oncolytics Biotech Gene Therapy in Oncology Introduction10.16.4 Oncolytics Biotech Revenue in Gene Therapy in Oncology Business (2015-2020)10.16.5 Oncolytics Biotech Recent Development13.17 Oncosec10.17.1 Oncosec Company Details10.17.2 Oncosec Business Overview and Its Total Revenue10.17.3 Oncosec Gene Therapy in Oncology Introduction10.17.4 Oncosec Revenue in Gene Therapy in Oncology Business (2015-2020)10.17.5 Oncosec Recent Development13.18 Oncotelic10.18.1 Oncotelic Company Details10.18.2 Oncotelic Business Overview and Its Total Revenue10.18.3 Oncotelic Gene Therapy in Oncology Introduction10.18.4 Oncotelic Revenue in Gene Therapy in Oncology Business (2015-2020)10.18.5 Oncotelic Recent Development13.19 Shenzhen SiBiono GeneTech10.19.1 Shenzhen SiBiono GeneTech Company Details10.19.2 Shenzhen SiBiono GeneTech Business Overview and Its Total Revenue10.19.3 Shenzhen SiBiono GeneTech Gene Therapy in Oncology Introduction10.19.4 Shenzhen SiBiono GeneTech Revenue in Gene Therapy in Oncology Business (2015-2020)10.19.5 Shenzhen SiBiono GeneTech Recent Development13.20 Sillajen Biotherapeutics10.20.1 Sillajen Biotherapeutics Company Details10.20.2 Sillajen Biotherapeutics Business Overview and Its Total Revenue10.20.3 Sillajen Biotherapeutics Gene Therapy in Oncology Introduction10.20.4 Sillajen Biotherapeutics Revenue in Gene Therapy in Oncology Business (2015-2020)10.20.5 Sillajen Biotherapeutics Recent Development13.21 Tocagen10.21.1 Tocagen Company Details10.21.2 Tocagen Business Overview and Its Total Revenue10.21.3 Tocagen Gene Therapy in Oncology Introduction10.21.4 Tocagen Revenue in Gene Therapy in Oncology Business (2015-2020)10.21.5 Tocagen Recent Development13.22 UniQure10.22.1 UniQure Company Details10.22.2 UniQure Business Overview and Its Total Revenue10.22.3 UniQure Gene Therapy in Oncology Introduction10.22.4 UniQure Revenue in Gene Therapy in Oncology Business (2015-2020)10.22.5 UniQure Recent Development13.23 Ziopharm Oncology10.23.1 Ziopharm Oncology Company Details10.23.2 Ziopharm Oncology Business Overview and Its Total Revenue10.23.3 Ziopharm Oncology Gene Therapy in Oncology Introduction10.23.4 Ziopharm Oncology Revenue in Gene Therapy in Oncology Business (2015-2020)10.23.5 Ziopharm Oncology Recent Development

14 Analysts Viewpoints/Conclusions

15 Appendix15.1 Research Methodology15.1.1 Methodology/Research Approach15.1.2 Data Source15.2 Disclaimer15.3 Author Details

Download Full Report https://www.qyresearchmedical.com/report/checkout/57077/3500

Contact Us:

QYResearch Medical

URL http://www.qyresearchmedical.com/

Mailing Address : Apt 1408 1785 Riverside Drive Ottawa, ON, K1G 3T7, Canada

Any Assistance, Email [emailprotected]

See more here:
Gene Therapy in Oncology Market New Research Study Report with Size, Share, Trends, Emerging Applications, Opportunities and Worldwide Analysis with...

Gene Therapy Market report would come handy to understand the competitors in the market and give an insight into sales, volumes, revenues in the Gene Therapy Industry & will also assists in making strategic decisions. The report also helps to decide corporate product & marketing strategies. It reduces the risks involved in making decisions as well as strategies for companies and individuals interested in the Gene Therapy industry. Both established and new players in Gene Therapy industries can use the report to understand the Gene Therapy market.

In Global Market, the Following Companies Are Covered:

Get a Sample Copy of the Report @ https://www.360marketupdates.com/enquiry/request-sample/14857391

Analysis of the Market:

Gene therapy is an experimental treatment that involves introducing genetic material into a persons cells to fight or prevent disease. Researchers are studying gene therapy for a number of diseases, such as severe combined immuno-deficiencies, hemophilia, Parkinsons disease, cancer and even HIV, through a number of different approaches. A gene can be delivered to a cell using a carrier known as a vector. The most common types of vectors used in gene therapy are viruses. The viruses used in gene therapy are altered to make them safe, although some risks still exist with gene therapy. The technology is still in its infancy.

Gene therapy is a method that involves introducing genetic material into a persons cells to fight or prevent diseases. In recent decades of years, researchers are paying more and more attention on it. Until today, it is still in infancy. There are many bio-technology companies entered into this market and carry on related research and development.

These research companies are including Bluebird Bio, Sangamom, Spark Therapeutics, Dimension Therapeutics, Avalanche Bio, Celladon, Vical and Advantagene. Among them, the top 5 research companies occupied more than 85% market.

Generally, the research fees of companies are come from their collaboration partners. For example, Bayer Healthcare is the partner of Dimension Therapeutics. General, some products of these companies are in the period 3 of their pipeline.

In general, cancer diseases are still the largest application with market share over 65% in 2015. In addition, there are some companies are focus on rare diseases.

Market Analysis and Insights: Global Gene Therapy Market

In 2019, the global Gene Therapy market is valued at considerable rate by the end of 2026, growing at a steady rate of CAGR during 2021-2026.

Global Gene Therapy Scope and Market Size

Gene Therapy market is segmented by Type, and by Application. Players, stakeholders, and other participants in the global Gene Therapy market will be able to gain the upper hand as they use the report as a powerful resource. The segmental analysis focuses on revenue and forecast by Type and by Application in terms of revenue and forecast for the period 2015-2026.

Segment by Type, the Gene Therapy market is segmented into Ex vivo, In Vivo, etc.

Segment by Application, the Gene Therapy market is segmented into Cancer, Monogenic, Infectious disease, Cardiovascular disease, Other, etc.

Regional and Country-level Analysis

The Gene Therapy market is analysed and market size information is provided by regions (countries).

The key regions covered in the Gene Therapy market report are North America, Europe, China, Japan, Southeast Asia, India and Central & South America, etc.

The report includes country-wise and region-wise market size for the period 2015-2026. It also includes market size and forecast by Type, and by Application segment in terms of revenue for the period 2015-2026.

Competitive Landscape and Gene Therapy Market Share Analysis

Gene Therapy market competitive landscape provides details and data information by vendors. The report offers comprehensive analysis and accurate statistics on revenue by the player for the period 2015-2020. It also offers detailed analysis supported by reliable statistics on revenue (global and regional level) by player for the period 2015-2020. Details included are company description, major business, company total revenue and the revenue generated in Gene Therapy business, the date to enter into the Gene Therapy market, Gene Therapy product introduction, recent developments, etc.

The major vendors include Bluebird Bio, Sangamo, Spark Therapeutics, Dimension Therapeutics, Avalanche Bio, Celladon, Vical Inc., Advantagene, etc.

This report focuses on the global Gene Therapy status, future forecast, growth opportunity, key market and key players. The study objectives are to present the Gene Therapy development in North America, Europe, China, Japan, Southeast Asia, India and Central & South America.

Gene Therapy Market Breakdown by Types:

s

Gene Therapy Market Breakdown by Application:

Critical highlights covered in the Global Gene Therapy market include:

The information available in the Gene Therapy Market report is segmented for proper understanding. The Table of contents contains Market outline, Market characteristics, Market segmentation analysis, Market sizing, customer landscape & Regional landscape. For further improving the understand ability various exhibits (Tabular Data & Pie Charts) has also been used in the Gene Therapy Market report.

Get a Sample Copy of the Report @ https://www.360marketupdates.com/enquiry/request-sample/14857391

Reasons for Buy Gene Therapy Market Report:

In the end, Gene Therapy Industry report provides the main region, market conditions with the product price,profit, capacity, production, supply, demand and market growth rateand forecast etc. This report also Present newproject SWOT analysis,investment feasibility analysis, andinvestment return analysis.

Contact Us:

Name: Mr. Ajay More

Email: [emailprotected]

Organization: 360 Market Updates

Phone: +14242530807 / + 44 20 3239 8187

Global Asphalt Modifiers Market Size 2020 research Reports collect information useful for the extensive, technical, market-oriented, commercial study Future Growth by 2026

Global MEMS Accelerometer for Consumer Electronics Market Size 2020 define, describe, and technology, application, end user, region, commercial study Future Growth by 2026

Global EVAR Stent Grafts Market Size 2020 research Reports collect information useful for the extensive, technical, market-oriented, commercial study Future Growth by 2026

Global Carbon Steel Tubing in Oil and Gas Lift Applications Market 2020: Industry Trends and Investigation Growth Rate, consumption by Regional data, Product & Application Segmentation, Key Companies and Analysis By 2026

Global In-Car Entertainment (Infotainment) (ICE) Systems Market 2020: Industry Trends and Investigation Growth Rate, consumption by Regional data, Product & Application Segmentation, Key Companies and Analysis By 2026

Chains and Sprockets in Material Handling Equipment Market 2020 Growth Analysis, Share, and consumption by Regional data, Investigation and Growth, Demand by Regions, Types and Analysis of Key Players- Research Forecasts To 2024

Global Regenerative Desiccant Dryers Market Size 2020 research Reports collect information useful for the extensive, technical, market-oriented, commercial study Future Growth by 2026

Global Synbiotic Foods Market Size 2020 Trend and Opportunities, Market Share, Analysis, CAGR and Value Chain Study, Showing Impressive Growth by 2024

Global Audience Targeting Software Market 2020 to Expand at a CAGR of by 2026: Analysis by Top Manufacturers, Product Type, Market Size & Growth, Focused Application

Read more:
Gene Therapy Market 2020 to Flourish with an Impressive CAGR of XX% in the year 2026, Predicts Market Research Future According to Current Market...

TipRanks

Expectations of good news on the near horizon are buoying markets right now. Over the past month, both the S&P 500 and the NASDAQ are up 11% to new record highs.Investors are excited at the prospect of a COVID vaccine coming before the winter is out. And the electoral results, that Democrat Joe Biden will ascend to the Presidency while the Republicans will emerge strengthened in Congress, promise the avoidance of extremes typical of divided government. In short, investors are looking forward to return to normal environment over the next several months. And that has them seeking stocks that are primed for gains. Against this backdrop, Goldman Sachs analysts are pounding the table on three stocks in particular, noting that each could surge over 40% in the year ahead. After running both tickers through TipRanks database, we found out that the rest of the Street is also standing squarely in the bull camp.Codiack BioSciences (CDAK)As we have all learned from coronavirus pandemic, some new thing in medical science can make huge impact on our world. Codiack aims to turn that principle to good. This research-oriented pharmaceutical aims to turn exosome therapeutics into a whole new class of medicines. Exosomes are the degradation mechanism RNA, and can transfer genetic material around a body.And therein lies the potential. Codiack has developed a design platform for the engineering of exosome proteins capable of carrying and protecting drug molecules through cell walls. In effect, the proteins will mimic the pathways used by viruses but are non-viral, and are designed to carry a payload of therapeutic agents. If successful, exosome therapy offers doctors the ability to design a drug that will deliver specific agents to specific cells to fight specific disease.Codiack is involved in all aspects of exosome therapeutics, from design to manufacturing, and currently has an active pipeline of agents seven, in all in various stages of discovery, preclinical testing, and the beginnings of Phase 1 trials.In the biosciences, success or failure is all about that pipeline, and in its diverse, active pipeline of agents in a new sector of biotechnological pharmaceuticals, Codiack has a fine resource to attract investors. To get those investors, the company went public this past October, selling 5.5 million shares at an opening price of $14.10 per share.Among the healthcare name's fans is Goldman Sachs analyst Graig Suvannavejh. The analyst wrote, Biopharma industry interest in exosomes has long been high, but engineering them for a specific function and manufacturing at scale have both proven challenging. Among a field of multiple competitors, CDAK has made the most significant progress on both fronts, and as such we view their technology platform as best-in-class."Given share underperformance (-37%) since the IPO, we find risk/reward highly compelling at current levels, and with key 2021 data sets to provide potential de-risking and positive share inflection," the analyst concluded.Suvannavejh rates CDAK a Buy, and his $29 price target shows the extent of his confidence it implies a 222% upside for the coming year. (To watch Suvannavejhs track record, click here)Overall, Codiack has a Strong Buy from the analyst consensus 3 reviewers have put up Buy ratings in recent weeks. The stock is selling for $8.90, and its $24 average price target implies a 166% one-year upside potential. (See CDAK stock analysis on TipRanks)Arcutis Biotherapeutics (ARQT)Acrutis is a pioneering researcher in the treatment of dermatological disease. Arcutis is involved in discovering the next generation of dermatological treatments an important niche, especially when one realizes that one common ailment, psoriasis, has not seen an FDA approval for a novel treatment in over two decades.The company is leveraging recent advances in immunology and inflammation to find new approaches to skin treatment. The goal is to make it easier for patients and doctors together to manage conditions like psoriasis, alopecia, atopic dermatitis, seborrheic dermatitis, and vitiligo, to name just a few.The company's lead candidate, ARQ-151 (roflumilast cream), is about to enter a phase 3 trial for atopic dermatitis, and is in an advanced phase 3 stage in Plaque Psoriasis. Arcutis has recently issued an update on positive data from the Phase 2 trials of ARQ-151 in atopic dermatitis. The drug is a once-daily treatment, and has demonstrated significant patient relief from symptoms, especially itching and itching-related sleep problems. This is another stock in Suvannavejhs coverage universe. The Goldman analyst is impressed by developments in the companys pipeline work, noting: ARQT provided an update on the outcome of its end-of-Phase 2 meetings with the FDA, following their Phase 2a trial of ARQ-151 in atopic dermatitis (AtD). Feedback from regulators was broadly encouraging, in particular, acknowledging the robust long-term safety data being generated by ARQT for ARQ-151 in plaque psoriasisAccordingly, Suvannavejh rates ARQT a Buy, and sets a $36 price target that indicates room for 40% upside growth in 2021. (To watch Suvannavejhs track record, click here)Arcutis has 2 recent Buy reviews, making the consensus rating a Moderate Buy. The stocks average price target is $37, suggesting a 44% upside from current levels. (See ARQT stock analysis on TipRanks)Oak Street Health (OSH)With the last stock, we move from medical research to medical care. Specifically, Oak Street Health is a primary care clinic operator, and part of the Medicare Network. The company has operations and clinics in Illinois, Indiana, Michigan, Pennsylvania, and Ohio, along with New York, North Carolina, Rhode Island, Tennessee, and Texas. It has been in operation for eight years, and went public this past summer, holding the IPO in August.In the third quarter, the companys first as a publicly traded entity, OSH brought in $217.9 million in revenue. The revenue number was up 56% from the year-ago quarter. Earnings per share matched expectations, at 15 cents.The companys expansion proceeds apace, and in October, Oak Street entered New York by opening, in Brooklyn, its 70th location. A planned expansion in Texas, involving a partnership with Walmart, is also proceeding as planned, and Oak Street has opened its first Walmart Community Clinic the Dallas-Fort Worth area city of Carrollton.Robert Jones, covering this stock for Goldman, set a $74 price target to back his Buy rating. At currently levels, this target implies an upside of ~58% in the next 12 months. (To watch Jones track record, click here)Results suggest operations are still on track, with few incremental updates since the 2Q call, where management noted a resumption of center openings, (pivoted) marketing efforts, and in-person visits despite COVID. In 3Q, OSH opened 13 new centers and is on track for 73-75 by end of year The company maintained that it is continuing to operate at a high level in places with elevated COVID case counts like Chicago and Detroit, Jones noted.All in all, the Strong Buy analyst consensus rating OSH is based on 8 reviews, breaking down to 7 Buys and just a single Hold. The stock is selling for $46.94, and its $61.29 average price target suggests it has a ~31% upside for the coming year. (See OSH stock analysis on TipRanks)To find good ideas for healthcare stocks trading at attractive valuations, visit TipRanks Best Stocks to Buy, a newly launched tool that unites all of TipRanks equity insights.Disclaimer: The opinions expressed in this article are solely those of the featured analysts. The content is intended to be used for informational purposes only. It is very important to do your own analysis before making any investment.

Read the original here:
Global Contract Cell and Gene Therapy Manufacturing Market Report 2020-2026: CDMO Categorization - Primed for Business Model Disruption - Yahoo...

The Most Recent study on the Hemophilia Gene Therapy Market Research provides a profound comprehension of the various market dynamics like trends, drivers, the challenges, and opportunities. The report further elaborates on the micro and macro-economic elements that are predicted to shape the increase of the Hemophilia Gene Therapy market throughout the forecast period (2019-2029).

The introduced study elucidates the crucial indicators of Market growth which comes with a thorough analysis of this value chain, CAGR development, and Porters Five Forces Analysis. This data may enable readers to understand the quantitative growth parameters of this international industry that is Hemophilia Gene Therapy .

Analytical Insights Included from the Hemophilia Gene Therapy Market Report

Request Sample Report @ https://www.factmr.co/connectus/sample?flag=S&rep_id=3107

Hemophilia Gene Therapy Market Segmentation Assessment

The increase prospects of this market in various Regions are studied in the report together with details like the regulatory framework, political, and financial outlook of each region.

Competitive landscape

Request Methodology On This Report @ https://www.factmr.co/connectus/sample?flag=RM&rep_id=3107

The COVID-19 pandemic has changed narratives related to growth and expansion across several key industries. Therefore, theHemophilia Gene Therapy market is also battling the cons of supply chain disruptions and procurement issues. Over the course of the next quarter, market players could be investing in new technologies to recover from the shocks of the pandemic.

The report provides a comprehensive account of the following key points:

The report also answers some of the burning questions pertaining to market expansion:

Ask analyst about this report at https://www.factmr.co/connectus/sample?flag=AE&rep_id=3107

The Report intends to eliminate the subsequent doubts regarding the Hemophilia Gene Therapy market:

Reasons To Choose Fact.MR:

Contact:

Unit No: AU-01-H Gold Tower (AU), Plot No: JLT-PH1-I3A,

Jumeirah Lakes Towers, Dubai, United Arab Emirates

MARKET ACCESS DMCC Initiative

Email:[emailprotected]

Web:https://www.factmr.com/

Read the original post:
Hemophilia Gene Therapy Market to Develop Rapidly by 2018 to 2028 - The Haitian-Caribbean News Network

Pune, India, Nov. 26, 2020 (GLOBE NEWSWIRE) -- The global mucopolysaccharidosis treatment market size is predicted to reach USD 4.37 billion by 2026, exhibiting a CAGR of 10.4% during the forecast period. The growing cases of rare diseases can be critical factor in fueling the demand for mucopolysaccharidosis treatment, which in turn, will aid the expansion of the market. The market in North America generated a revenue of USD 1,019.4 million in 2018. The growth in the region is attributed to the higher diagnosis and treatment rates for a number of rare disorders.

KEY INDUSTRY DEVELOPMENTS:

Request a Sample Copy of the Research Report: https://www.fortunebusinessinsights.com/enquiry/request-sample-pdf/mucopolysaccharidosis-treatment-market-102551

Unmet Clinical Needs to Influence Market Growth

The growing necessity for advanced therapeutics will impel companies to launch novel therapies, which in turn, will boost the mucopolysaccharidosis treatment market growth in the forthcoming years. Moreover, the growing unmet clinical needs of patients along with better treatment outcomes will spur demand for mucopolysaccharidosis treatment market during the forecast period.

Moreover, the increasing acquisitions and deals between key players will bolster healthy growth of the market. For instance, in April 2019, GC Pharma announced the signing of a licensing deal with Clinigen KK in Japan for their product offering of Hunterase ICV, which is used for the treatment of Mucopolysaccharidosis Type II (Hunter syndrome).

In addition, the increasing R&D by pharmaceutical companies for the mass production of conventional medications or therapies to treat diseases such as heart disease and diabetes along with rare disorders such as the types of mucopolysaccharidosis. This factor will aid the mucopolysaccharidosis treatment market revenue in the foreseeable future.

Click here to get the short-term and long-term impact of COVID-19 on this Market.

Please visit: https://www.fortunebusinessinsights.com/mucopolysaccharidosis-treatment-market-102551

Increasing Prevalence of Rare Diseases to Stimulate Growth in North America

The market in North America generated a revenue of USD 1,019.4 million in 2018. The growth in the region is attributed to the higher diagnosis and treatment rates for a number of rare disorders. The favorable reimbursement policies for such therapies will also have a weighty impact on the market in North America.

The rising awareness among patient population towards advanced treatment options will also spur demand for mucopolysaccharidosis treatment market. The presence of significant players and biopharmaceutical companies along with ongoing clinical trials will further augment growth in North America. Europe is predicted to witness high growth during the forecast period owing to the high sales of Elaprase and ALDURAZYME in the region.

Asia Pacific is predicted to grow significantly due to launch of novel therapeutics such as Hunterase in Japan. The growing patient population in various countries will enable growth of the market in the region.

Quick Buy - Mucopolysaccharidosis Treatment Market Research Report: https://www.fortunebusinessinsights.com/checkout-page/102551

The Report Lists the Key Companies in the Mucopolysaccharidosis Treatment Market

Global Mucopolysaccharidosis Treatment Market Segmentations:

By Treatment

Enzyme Replacement Therapy (ERT)

Others

By Disease Type

Mucopolysaccharidosis Type I

Mucopolysaccharidosis Type II

Mucopolysaccharidosis Type IV A

Mucopolysaccharidosis Type VI

Others

By Route of Administration

Intravenous

Intracerebroventricular (ICV)

By End User

Hospitals

Specialty Clinics

Others

By Geography

North America (U.S. and Canada)

Europe (U.K., Germany, France, Italy, Spain, and Rest of Europe)

Asia-Pacific (Japan, China, India, South Korea, and Rest of Asia-Pacific)

Rest of the World

Have Any Query? Ask Our Experts: https://www.fortunebusinessinsights.com/enquiry/speak-to-analyst/mucopolysaccharidosis-treatment-market-102551

SECONDARY DATA SOURCES THAT WE REFER TO:

SECONDARY RESEARCH IS CONDUCTED TO DERIVE THE FOLLOWING INFORMATION:

Get your Customized Research Report: https://www.fortunebusinessinsights.com/enquiry/customization/mucopolysaccharidosis-treatment-market-102551

Have a Look at Related Reports:

Injectable Drug Delivery Market Share and Global Trend By Device Type (Conventional Injectable, Pre-filled Syringes, Auto-injectors, Pen-injectors, Others), By Application (Autoimmune Disorders, Diabetes, Pain Management, Aesthetic Treatments, Others), By Route of Administration (Subcutaneous, Intravenous, Intramuscular, Others), By End-User (Hospitals, Home Care Settings, Clinics, Others) and Geography Forecast till 2026

Psoriasis Treatment Market Share and Global Trend By Drug Class (TNF Inhibitors, Interleukins, Others), By Type (Plaque Psoriasis, Psoriatic Arthritis, Others), By Route of Administration (Oral, Parenteral, Topical), By Distribution Channel (Hospital Pharmacies, Retail Pharmacies, Online pharmacies), and Geography Forecast till 2026

Medical Lasers Market Share and Global Trend By Type (Surgical Lasers, Dental Lasers, Aesthetic Lasers, Others), By Product (Laser Systems, Consumables), By End User (Hospitals, Specialty Clinics) and Geography Forecast till 2026

Telehealth Market Share and Global Trend By Type (Products, Services), By Application (Telemedicine, Patient Monitoring, Continuous Medical Education, Others), By Modality (Store-and-forward (Asynchronous), Real-time (Synchronous), Remote Patient Monitoring), By End User (Healthcare Facilities, Homecare, Others), and Geography Forecast till 2026

Clear Aligners Market Share and Global Trend By Patient Age Group (Teenager, Adults), By End-User (Hospitals, Dental & Orthodontic Clinics) and Geography Forecast till 2026

About Us:

Fortune Business Insights offers expert corporate analysis and accurate data, helping organizations of all sizes make timely decisions. We tailor innovative solutions for our clients, assisting them to address challenges distinct to their businesses. Our goal is to empower our clients with holistic market intelligence, giving a granular overview of the market they are operating in.

Our reports contain a unique mix of tangible insights and qualitative analysis to help companies achieve sustainable growth. Our team of experienced analysts and consultants use industry-leading research tools and techniques to compile comprehensive market studies, interspersed with relevant data.

At Fortune Business Insights we aim at highlighting the most lucrative growth opportunities for our clients. We, therefore, offer recommendations, making it easier for them to navigate through technological and market-related changes. Our consulting services are designed to help organizations identify hidden opportunities and understand prevailing competitive challenges.

Contact Us:

Fortune Business Insights Pvt. Ltd. 308, Supreme Headquarters, Survey No. 36, Baner, Pune-Bangalore Highway, Pune - 411045, Maharashtra, India.

Phone:US :+1 424 253 0390UK : +44 2071 939123APAC : +91 744 740 1245Email: sales@fortunebusinessinsights.comFortune Business InsightsLinkedIn | Twitter | Blogs

Press Release: https://www.fortunebusinessinsights.com/press-release/mucopolysaccharidosis-treatment-market-9710

Read the original post:
Mucopolysaccharidosis Treatment Market to Exhibit a CAGR of 10.4% and Hit USD 4.37 Billion by 2026; Growing Cases of Rare Diseases to Spur Business...

"Despite the projected growth in market applications and abundant investment capital, there is a danger that legal and ethical concerns related to genetic research could put the brakes on gene editing technologies and product programs emanating therefrom."

What is Genome Editing?

There are thousands of diseases occurring in humans, animals, and plants caused by aberrant DNA sequences. Traditional small molecule and biologic therapies have only had minimal success in treating many of these diseases because they mitigate symptoms while failing to address the underlying genetic causes. While human understanding of genetic diseases has increased tremendously since the mapping of the human genome in the late 1990s, our ability to treat them effectively has been limited by our historical inability to alter genetic sequences.

The science of gene editing was born in the 1990s, as scientists developed tools such as zinc-finger nucleases (ZFNs) and TALE nucleases (TALENs) to study the genome and attempt to alter sequences that caused disease. While these systems were an essential first step to demonstrate the potential of gene editing, their development was challenging in practice due to the complexity of engineering protein-DNA interactions.

Then, in 2011, Dr. Emmanuelle Charpentier, a French professor of microbiology, genetics, and biochemistry, and Jennifer Doudna, an American professor of biochemistry, pioneered a revolutionary new gene-editing technology called CRISPR/Cas9. Clustered Regularly Interspaced Short Palindromic Repeats (CRISPR) and Cas9 stands for CRISPR-associated protein 9. In 2020, the revolutionary work of Drs. Charpentier and Doudna developing CRISPR/Cas9 were recognized with the Nobel Prize for Chemistry. The technology was also the source of a long-running and high-profile patent battle between two groups of scientsists.

CRISPR/Cas9 for gene editing came about from a naturally occurring viral defense mechanism in bacteria. The system is cheaper and easier to use than previous technologies. It delivers the Cas9 nuclease complexed with a synthetic guide RNA (gRNA) into a cell, cutting the 'cell's genome at the desired location, allowing existing genes to be removed and new ones added to a living organism's genome. The technique is essential in biotechnology and medicine as it provides for the genomes to be edited in vivo with extremely high precision, efficiently, and with comparative ease. It can create new drugs, agricultural products, and genetically modified organisms or control pathogens and pests. More possibilities include the treatment of inherited genetic diseases and diseases arising from somatic mutations such as cancer. However, its use in human germline genetic modification is highly controversial.

The following diagram from CRISPR Therapeutics AG, a Swiss company, illustrates how it functions:

Market Applications

In the 1990s, nanotechnology and gene editing were necessary plot points for science fiction films. In 2020, developments like nano-sensors and CRISPR gene editing technology have moved these technologies directly into the mainstream, opening a new frontier of novel market applications. According to The Business Research Company, the global CRISPR technology market reached a value of nearly $700 million in 2019, is expected to more than double in 2020, and reach $6.7 billion by 2030. Market applications target all forms of life, from animals to plants to humans.

Gene editing's primary market applications are for the treatment of genetically-defined diseases. CRISPR/Cas9 gene editing promises to enable the engineering of genomes of cell-based therapies and make them safer and available to a broader group of patients. Cell therapies have already begun to make a meaningful impact on specific diseases, and gene editing helps to accelerate that progress across diverse disease areas, including oncology and diabetes.

In the area of human therapy, millions of people worldwide suffer from genetic conditions. Gene-editing technologies like CRISPR-Cas9 have introduced a way to address the cause of debilitating illnesses like cystic fibrosis and create better interventions and therapies. They also have promising market applications for agriculture, food safety, supply, and distribution. For example, grocery retailers are even looking at how gene editing could impact the products they sell. Scientists have created gene-edited crops like non-browning mushrooms and mildew-resistant grapes - experiments that are part of an effort to prevent spoilage, which could ultimately change the way food is sold.

Investment Capital

Despite the inability to travel and conduct face-to-face meetings, attend industry conferences or conduct business other than remotely or with social distance, the investment markets for venture, growth, and private equity capital, as well as corporate R&D budgets, have remained buoyant through 2020 to date. Indeed, the third quarter of 2020 was the second strongest quarter ever for VC-backed companies, with 88 companies raising rounds worth $100 million or more according to the latest PwC/Moneytree report. Healthcare startups raised over $8 billion in the quarter in the United States alone. Gene-editing company Mammouth Biosciences raised a $45 million round of Series B capital in the second quarter of 2020. CRISPR Therapeutics AG raised more in the public markets in primary and secondary capital.

Bayer, Humboldt Fund and Leaps are co-leading a $65 million Series A round for Metagenomi, a biotech startup launched by UC Berkeley scientists. Metagenomi, which will be run by Berkeley's Brian Thomas, is developing a toolbox of CRISPR- and non-CRISPR-based gene-editing systems beyond the Cas9 protein. The goal is to apply machine learning to search through the genomes of these microorganisms, finding new nucleases that can be used in gene therapies. Other investors in the Series A include Sozo Ventures, Agent Capital, InCube Ventures and HOF Capital. Given the focus on new therapies and vaccines to treat the novel coronavirus, we expect continued wind in the sails for gene-editing companies, particularly those with strong product portfolios that leverage the technology.

Legal and Ethical Considerations

Despite the projected growth in market applications and abundant investment capital, there is a danger that legal and ethical concerns related to genetic research could put the brakes on gene-editing technologies and product programs emanating therefrom. The possibility of off-target effects, lack of informed consent for germline therapy, and other ethical concerns could cause government regulators to put a stop on important research and development required to cure disease and regenerate human health.

Gene-editing companies can only make money by developing products that involve editing the human genome. The clinical and commercial success of these product candidates depends on public acceptance of gene-editing therapies for the treatment of human diseases. Public attitudes could be influenced by claims that gene editing is unsafe, unethical, or immoral. Consequently, products created through gene editing may not gain the acceptance of the government, the public, or the medical community. Adverse public reaction to gene therapy, in general, could result in greater government regulation and stricter labeling requirements of gene-editing products. Stakeholders in government, third-party payors, the medical community, and private industry must work to create standards that are both safe and comply with prevailing ethical norms.

The most significant danger to growth in gene-editing technologies lies in ethical concerns about their application to human embryos or the human germline. In 2016, a group of scientists edited the genome of human embryos to modify the gene for hemoglobin beta, the gene in which a mutation occurs in patients with the inherited blood disorder beta thalassemia. Although conducted in non-viable embryos, it shocked the public that scientists could be experimenting with human eggs, sperm, and embryos to alter human life at creation. Then, in 2018, a biophysics researcher in China created the first human genetically edited babies, twin girls, causing public outcry (and triggering government sanctioning of the researcher). In response, the World Health Organization established a committee to advise on the creation of standards for gene editing oversight and governance standards on a global basis.

Some influential non-governmental agencies have called for a moratorium on gene editing, particularly as applied to altering the creation or editing of human life. Other have set forth guidelines on how to use gene-editing technologies in therapeutic applications. In the United States, the National Institute of Health has stated that it will not fund gene-editing studies in human embryos. A U.S. statute called "The Dickey-Wicker Amendment" prohibits the use of federal funds for research projects that would create or destroy human life. Laws in the United Kingdom prohibit genetically modified embryos from being implanted into women. Still, embryos can be altered in research labs under license from the Human Fertilisation and Embryology Authority.

Regulations must keep pace with the change that CRISPR-Cas9 has brought to research labs worldwide. Developing international guidelines could be a step towards establishing cohesive national frameworks. The U.S. National Academy of Sciences recommended seven principles for the governance of human genome editing, including promoting well-being, transparency, due care, responsible science, respect for persons, fairness, and transnational co-operation. In the United Kingdom, a non-governmental organization formed in 1991 called The Nuffield Council has proposed two principles for the ethical acceptability of genome editing in the context of reproduction. First, the intervention intends to secure the welfare of the individual born due to such technology. Second, social justice and solidarity principles are upheld, and the intervention should not result in an intensifying of social divides or marginalizing of disadvantaged groups in society. In 2016, in application of the same, the Crick Institute in London was approved to use CRISPR-Cas9 in human embryos to study early development. In response to a cacophony of conflicting national frameworks, the International Summit on Human Gene Editing was formed in 2015 by NGOs in the United States, the United Kingdom and China, and is working to harmonize regulations global from both the ethical and safety perspectives. As CRISPR co-inventor Jennifer Doudna has written in a now infamous editorial in SCIENCE, "stakeholders must engage in thoughtfully crafting regulations of the technology without stifling it."

Where Do We Go from Here?

The COVID-19 pandemic has forced us to rely more on new technologies to keep us healthy, adapt to working from home, and more. The pandemic makes us more reliant on innovative digital, biological, and physical solutions. It has created a united sense of urgency among the public and private industry (together with government and academia) to be more creative about using technology to regenerate health. With continued advances in computing power, network architecture, communications bandwidths, artificial intelligence, machine learning, and gene editing, society will undoubtedly find more cures for debilitating disease and succeed in regenerating human health. As science advances, it inevitably intersects with legal and ethical norms, both for individuals and civil society, and there are new externalities to consider. Legal and ethical norms will adapt, rebalancing the interests of each. The fourth industrial revolution is accelerating, and hopefully towards curing disease.

Originally published by IPWatchdog.com, November 24, 2020.

The content of this article is intended to provide a general guide to the subject matter. Specialist advice should be sought about your specific circumstances.

Mr Louis LehotL2 Counsel407 California Avenue, Suite #2Palo AltoCaliforniaUNITED STATESTel: 6507967280E-mail: louis.lehot@L2counsel.comURL: http://www.l2counsel.com/

Mondaq Ltd, 2020 - Tel. +44 (0)20 8544 8300 - http://www.mondaq.com, source Business Briefing

Read this article:
Future Visioning The Role Of CRISPR Gene Editing: Navigating Law And Ethics To Regenerate Health And Cure Disease - marketscreener.com

Fort Collins, Colorado The The Future of Global Gene Therapy Market 2020 Research Report provides information on the market size, share, trends, growth, competitive landscape, challenges and opportunities, revenue, and forecast to 2027. Reports Globe recently incorporated a comprehensive overview of the The Future of Global Gene Therapy market into its extensive database. The The Future of Global Gene Therapy Market report has been aggregated by collecting informative data on various dynamics such as market drivers, restraints, and opportunities.

This innovative report uses SWOT, PESTLE, and Porters Five Forces analysis to get a deeper look at the The Future of Global Gene Therapy market.

Download Exclusive Sample PDF along with few company profiles @ https://reportsglobe.com/download-sample/?rid=21308

The Major Players Profiled in this Report include

Impact of Covid-19 on this Market:

The coronavirus pandemic (COVID-19) has affected all aspects of life around the world. The study provides a comprehensive overview of the impact of the COVID-19 pandemic on the The Future of Global Gene Therapy market and its key segments. It also covers the current and future impact of the pandemic and offers a post-COVID-19 scenario to provide a deeper understanding of the dynamic changes in market trends and scenarios.

Competitive Landscape:

Competitive Analysis is one of the best sections of the report, comparing the progress of leading companies using key metrics like market share, new developments, global reach, local competition, pricing, and production. . From the nature of the competition to future changes in the vendor landscape, the report offers an in-depth competitive analysis in the global The Future of Global Gene Therapy Market.

Request a Discount on the report @ https://reportsglobe.com/ask-for-discount/?rid=21308

Market Segments and Sub-segments Covered in the Report are as per below:

Research Methodology:

Reports Globe follows a comprehensive research methodology to provide the most accurate market analysis. The company relies on a data triangulation model that can be used to assess market dynamics and provide accurate estimates. Key elements of the research methodology used for all of our market reports include:

Request customization of the report @https://reportsglobe.com/need-customization/?rid=21308

In addition, Reports Globe has access to a wide range of reputable regional and global paid databases that help the company understand regional and global market trends and dynamics. The company analyzes the industry from a 360-degree perspective, i.e. H. From the supply and demand side, which allows us to provide detailed information about the entire ecosystem for each study. Finally, a top-down and bottom-up approach is taken to get the final search results.

It includes analysis on the following

Finally, the The Future of Global Gene Therapy Market Report is a credible source of market research that will accelerate your business exponentially. The report gives the most important regional framework conditions, economic situations with item value, advantage, limit, production, supply, demand, market development rate and number, etc. The Future of Global Gene Therapy Industry Report Also includes a new SWOT review task, speculative test research, and corporate return on investment research.

To learn more about the report, visit @ https://reportsglobe.com/product/the-future-of-global-gene-therapy-market/

Thanks for reading this article; you can also get individual chapter wise section or region wise report versions like North America, Europe, or Asia.

How Reports Globe is different than other Market Research Providers

The inception of Reports Globe has been backed by providing clients with a holistic view of market conditions and future possibilities/opportunities to reap maximum profits out of their businesses and assist in decision making. Our team of in-house analysts and consultants works tirelessly to understand your needs and suggest the best possible solutions to fulfill your research requirements.

Our team at Reports Globe follows a rigorous process of data validation, which allows us to publish reports from publishers with minimum or no deviations. Reports Globe collects, segregates, and publishes more than 500 reports annually that cater to products and services across numerous domains.

Contact us:

Mr. Mark Willams

Account Manager

US: +1-970-672-0390

Email:[emailprotected]

Web:reportsglobe.com

See original here:
The Future of Global Gene Therapy Market To Observe Exponential Growth By 2020-2027 | Reports Globe - Cheshire Media

DBMR has added a new report titled Global Prostate Cancer Therapeutics Market with data Tables for historical and forecast years represented with Chats & Graphs spread through Pages with easy to understand detailed analysis. The Global Prostate Cancer Therapeutics Market report provides the list of leading competitors, strategic industry analysis and the insights of key factors influencing the industry. The market analysis and insights included in this Global Prostate Cancer Therapeutics Market research report offers key statistics on the market status of global and regional manufacturers and is an imperative source of guidance which provides right direction to the companies and individuals interested in the industry. This Global Prostate Cancer Therapeutics Market report is also all-embracing of the data which includes market definition, classifications, applications, engagements, market drivers and market restraints that are obtained with the help of SWOT analysis.

Market drivers and market restraints explained in this Global Prostate Cancer Therapeutics Market business research report provides idea about the rise or fall in the consumer demand for the particular product depending on several factors. Thoroughly described market segmentation aspect provides a clear idea about the product consumption based on several factors ranging from type, application, deployment model, end user to geographical region. This Global Prostate Cancer Therapeutics Market report also presents an analysis of prime manufacturers, trends, opportunities, marketing strategies, market effect factor and consumer needs by major regions, types, and applications globally while considering the past, present and future state of the industry.

Prostate cancer therapeutics market is expected to gain market growth in the forecast period of 2020 to 2027. Data Bridge Market Research analyses the market to reach a market value of USD 18.71 billion by 2027 while growing at a CAGR of 7.70% in the above-mentioned forecast period. Prostate cancer therapeutics market is growing due to factor such as increasing cases of prostate cancer and cardiovascular diseases.

Get Sample Report + All Related Graphs & Charts @https://www.databridgemarketresearch.com/request-a-sample?dbmr=global-prostate-cancer-therapeutics-market

Some of the major players operating in the global prostate cancer therapeutics market are Tolmar INC, Ferring Pharmaceuticals, Takeda pharmaceutical co. Ltd., Teva Pharmaceutical Industries LTD, Sanofi-Aventis, Pfizer Inc, Johnson & Johnson, IPSEN, Endo Pharmaceuticals Inc (Indevus Pharmaceuticals Inc) , Dendreon Corporation, Bristol-Myers Squibb, Astellas Pharma Inc, Astrazeneca Plc, Active Biotech, Abbott Laboratories, Bayer AG, Dendreon Corporation (Sanpower Group Co. Ltd.), AbbVie, Inc. among others.

Global Prostate Cancer Therapeutics Market By Drug Class (Hormonal Therapy, Chemotherapy, Immunotherapy, Targeted Therapy), Distribution Channel (Hospital Pharmacies, Retail Pharmacies, Online Sales, Others), Country (U.S., Canada, Mexico, Germany, Italy, U.K., France, Spain, Netherland, Belgium, Switzerland, Turkey, Russia, Hungary, Lithuania, Austria, Ireland, Norway, Poland, Rest of Europe, Japan, China, India, South Korea, Australia, Singapore, Malaysia, Thailand, Indonesia, Philippines, Vietnam, Rest of Asia- Pacific, Brazil, Peru, Argentina, Rest of South America, South Africa, Saudi Arabia, UAE, Kuwait, Egypt, Israel, Rest of Middle East & Africa), Market Trends and Forecast to 2027

Market Definition:Global Prostate Cancer Therapeutics Market

The prostate cancer occurs in the prostate which is a small walnut shaped gland. The prostate cancer is most common type in men. Due to increase in awareness regarding the symptoms among the people, the market for the prostate cancer therapeutics is growing at a high growth rate. Various developments in advance science are helping in development of launch of various options for the treatment of this disease. According to an article published recently by the cancer research institute in U.K., around 11,287 deaths were registered due to prostate cancer in U.K. The prostate cancer is the fourth most prevalent cancer globally. Various researches are made by the key player for the development of the therapies for the treatment of the cancer. The government is also taking various measures for the awareness regarding symptoms of the prostate cancer and availability of screening & diagnostic tests such as Prostate-Specific Antigen (PSA) and Digital Rectal Exam (DRE) resulting in early detection. Hence, such initiatives by the government and the key players help in the growth of the market.

Increasing awareness among people regarding prostate cancer along with technological advancement in screening and diagnostic tests, rising preferences of healthy living will increased geriatric population will enhance the growth of the prostate cancer therapeutics market in the forecast period of 2020-2027. On the other hand, limited number of players, increasing pharmaceutical expenditure will further create new opportunities for the growth of prostate cancer therapeutics market in the above mentioned forecast period.

Increasing cost of the treatment and adverse impact of treatment along with less success rate will acts as a restraint factor for the growth of prostate cancer therapeutics market in the above mentioned forecast period.

Competitive Landscape and Prostate Cancer Therapeutics Market Share Analysis

Prostate cancer therapeutics market competitive landscape provides details by competitor. Details included are company overview, company financials, revenue generated, market potential, investment in research and development, new market initiatives, global presence, production sites and facilities, production capacities, company strengths and weaknesses, product launch, product width and breadth, application dominance. The above data points provided are only related to the companies focus related to prostate cancer therapeutics market.

Market Segmentation:Global Prostate Cancer Therapeutics Market

The global prostate cancer therapeutics market is segmented based on drug type, distribution channel and geographical segments.

On the basis of drug type, the market is classified into hormonal therapy, luteinizing hormone-releasing hormone (LHRH) agonist, anti-androgens, immunotherapy, targeted therapy, and chemotherapy

On the basis of distribution channel, the market is segmented into hospital pharmacies, retail pharmacies, and online pharmacies.

Based on geography, the global prostate cancer therapeutics market report covers data points for 28 countries across multiple geographies namely North America & South America, Europe, Asia-Pacific and, Middle East & Africa. Some of the major countries covered in this report are U.S., Canada, Germany, France, U.K., Netherlands, Switzerland, Turkey, Russia, China, India, South Korea, Japan, Australia, Singapore, Saudi Arabia, South Africa and, Brazil among others.

Key Developments in the Market:

Grab Your Report at an Impressive 30% Discount! Please click Here @https://www.databridgemarketresearch.com/inquire-before-buying?dbmr=global-prostate-cancer-therapeutics-market

Prostate Cancer Therapeutics Market Country Level Analysis

Prostate cancer therapeutics market is analysed and market size insights and trends are provided by country, drug class and distribution channel as referenced above.

The countries covered in the prostate cancer therapeutics market report are U.S., Canada and Mexico in North America, Germany, France, U.K., Netherlands, Switzerland, Belgium, Russia, Italy, Spain, Turkey, Hungary, Lithuania, Austria, Ireland, Norway, Poland, Rest of Europe in Europe, China, Japan, India, South Korea, Singapore, Malaysia, Australia, Thailand, Indonesia, Philippines, Vietnam, Rest of Asia-Pacific (APAC) in the Asia-Pacific (APAC), Saudi Arabia, U.A.E, South Africa, Kuwait, Egypt, Israel, Rest of Middle East and Africa (MEA) as a part of Middle East and Africa (MEA), Peru, Brazil, Argentina and Rest of South America as part of South America.

North America dominates the prostate cancer therapeutics market due to increasing occurrence of prostate cancer and high mortality rate along with rising investment in research and development of advanced solutions while Asia-Pacific will witness a growth in forecast period of 2020-2027 because of increasing awareness among people regarding tumours and improvement in healthcare infrastructure in this regions.

The country section of the prostate cancer therapeutics market report also provides individual market impacting factors and changes in regulation in the market domestically that impacts the current and future trends of the market. Data points such as consumption volumes, production sites and volumes, import export analysis, price trend analysis, cost of raw materials, down-stream and upstream value chain analysis are some of the major pointers used to forecast the market scenario for individual countries. Also, presence and availability of global brands and their challenges faced due to large or scarce competition from local and domestic brands, impact of domestic tariffs and trade routes are considered while providing forecast analysis of the country data.

Patient Epidemiology Analysis

Prostate cancer therapeutics market also provides you with detailed market analysis for patient analysis, prognosis and cures. Prevalence, incidence, mortality, adherence rates are some of the data variables that are available in the report. Direct or indirect impact analysis of epidemiology to market growth are analysed to create a more robust and cohort multivariate statistical model for forecasting the market in the growth period.

Major Market Drivers and Restraints:

Reasons to Purchase this Report

Customization of the Report

About Data Bridge Market Research:

Data Bridge Market Research set forth itself as an unconventional and neoteric Market research and consulting firm with unparalleled level of resilience and integrated approaches. We are determined to unearth the best market opportunities and foster efficient information for your business to thrive in the market. Data Bridge endeavors to provide appropriate solutions to the complex business challenges and initiates an effortless decision-making process.

Contact:

Data Bridge Market Research

US: +1 888 387 2818

UK: +44 208 089 1725

Hong Kong: +852 8192 7475

Email: Corporatesales@databridgemarketresearch.com

This content has been distributed via CDN Newswire press release distribution service. For press release enquires please mail us at contact@cdnnewswire.com.

Read more:
Global Prostate Cancer Therapeutics Market Size And Forecast (2020-2026)| With Post Impact Of Covid- - PharmiWeb.com

The Cancer Gene Therapy Market grew in 2019, as compared to 2018, according to our report, Cancer Gene Therapy Market is likely to have subdued growth in 2020 due to weak demand on account of reduced industry spending post Covid-19 outbreak. Further, Cancer Gene Therapy Market will begin picking up momentum gradually from 2021 onwards and grow at a healthy CAGR between 2021-2025

Deep analysis about market status (2016-2019), competition pattern, advantages and disadvantages of products, industry development trends (2019-2025), regional industrial layout characteristics and macroeconomic policies, industrial policy has also been included. From raw materials to downstream buyers of this industry have been analysed scientifically. This report will help you to establish comprehensive overview of the Cancer Gene Therapy Market

Get a Sample Copy of the Report at: https://i2iresearch.com/report/global-cancer-gene-therapy-market-2020-market-size-share-growth-trends-forecast-2025/#download-sample

The Cancer Gene Therapy Market is analysed based on product types, major applications and key players

Key product type:Oncolytic VirotherapyGene TransferGene-Induced Immunotherapy

Key applications:HospitalsDiagnostics CentersResearch Institutes

Key players or companies covered are:AdaptimmuneBluebird bioCelgeneShanghai Sunway BiotechShenzhen SiBiono GeneTechSynerGene TherapeuticsAltor BioScienceAmgenArgenxBioCancellGlaxoSmithKlineMerckOncoGenex PharmaceuticalsTransgene

The report provides analysis & data at a regional level (North America, Europe, Asia Pacific, Middle East & Africa , Rest of the world) & Country level (13 key countries The U.S, Canada, Germany, France, UK, Italy, China, Japan, India, Middle East, Africa, South America)

Inquire or share your questions, if any: https://i2iresearch.com/report/global-cancer-gene-therapy-market-2020-market-size-share-growth-trends-forecast-2025/

Key questions answered in the report:1. What is the current size of the Cancer Gene Therapy Market, at a global, regional & country level?2. How is the market segmented, who are the key end user segments?3. What are the key drivers, challenges & trends that is likely to impact businesses in the Cancer Gene Therapy Market?4. What is the likely market forecast & how will be Cancer Gene Therapy Market impacted?5. What is the competitive landscape, who are the key players?6. What are some of the recent M&A, PE / VC deals that have happened in the Cancer Gene Therapy Market?

The report also analysis the impact of COVID 19 based on a scenario-based modelling. This provides a clear view of how has COVID impacted the growth cycle & when is the likely recovery of the industry is expected to pre-covid levels.

Contact us:i2iResearch info to intelligenceLocational Office: *India, *United States, *GermanyEmail: [emailprotected]Toll-free: +1-800-419-8865 | Phone: +91 98801 53667

Read the rest here:
Cancer Gene Therapy Market Research Report with Revenue, Gross Margin, Market Share and Future Prospects till 2026 - Cheshire Media

Vivet Therapeutics and Pfizer are one step closer to bringing a gene therapy for a rare liver disorder into the clinic.

The companies announced Wednesday morning that the FDA has accepted its IND application for a Phase I/II study in the treatment of Wilsons disease. The study, evaluating a program dubbed VTX-801, is expected to launch early next year.

VTX-801 is an rAAV-based gene therapy vector designed to deliver a protein called ATP7B in the hopes of restoring copper homeostasis, reversing liver pathology and reducing copper accumulation in the brain, as it was shown to do in mouse models.

The study will be open label and not be randomized. Researchers will give a one-time IV infusion of the gene therapy in up to 16 adult patients, with the goal of evaluating three different dosage levels. Ultimately, the companies set a primary endpoint for safety and tolerability after 52 weeks.

In March 2019, Pfizer acquired a minority stake in the company, and in September, the big pharma agreed to manufacture the VTX-801 vector for this Phase I/II study. Max Gelman

Florida-based biotech Generex has inked the biggest deal (it) could even imagine, bagging $50 million from a consortium of Chinese institutions that licensed its Ii-Key vaccine tech for infectious diseases and cancer.

Comprising hybrid peptides and a suppression, the platform has spawned a vaccine candidate against SARS-CoV-2 in addition to a pipeline of immuno-oncology therapies.

We are able to generate a detailed immune activation profile of our Ii-Key vaccine candidates by screening blood samples from COVID-19 recovered patients, explained Richard Purcell, EVP of R&D.

In addition to the upfront fee for the overall deal, the unnamed partners have handed over $5 million to license the Covid-19 vaccine candidate and promised a $20 million success fee if its approved in China. Separate contracts for the other indications are being finalized. Amber Tong

Here is the original post:
News briefing: Pfizer and Vivet get the OK to start gene therapy trial for rare liver disorder; Florida biotech inks $50M China deal - Endpoints News

Avrobio has shared data on the first Gaucher disease patient to receive its gene therapy AVR-RD-02. The patient, who was stable on enzyme replacement therapy at baseline, experienced a 22% drop in a toxic metabolite after receiving AVR-RD-02 and stopping taking the standard of care.

Gaucher, like the Fabry disease targeted by Avrobios lead prospect, is currently treated using enzyme replacement therapies sold by Sanofi and Takeda, which entered the market through its takeover of Shire. However, a significant minority of patients experience physical limitations despite treatment. Negative outcomes include bone pain and spleen enlargement. Johnson & Johnsons Zavesca offers an oral alternative, but there remain unmet medical needs.

Avrobio is developing AVR-RD-02 to address those needs. The data shared as part of Avrobios R&D day mark the start of the effort to show AVR-RD-02 performs as hoped in the clinic.

Start using real-world data to advance your clinical research

Much has been written about the promise of real-world data (RWD) in life sciences, but how does it work in practice? We address this question in a new whitepaper that demonstrates the potential benefits of new RWD technologies with a proof of concept study to show how RWD can be incorporated into clinical research.

The first patient to receive AVR-RD-02 discontinued enzyme replacement therapy one month before taking the gene therapy. Three months after receiving the gene therapy, levels of Gaucher biomarker lyso-Gb1 had fallen 22%. The patients level of plasma chitotriosidase, a biomarker of cells associated with severe organ damage, was down 17%. Hemoglobin and platelets were in the normal range.

AVR-RD-02 triggered those changes without causing serious adverse events. The data drop offers an early indication that Avrobio may be able to improve outcomes by harvesting hematopoietic stem cells, adding a gene that encodes for glucocerebrosidase and reinfusing the cells back into the same patient. With enzyme replacement therapies costing healthcare systems up to $400,000 a year per patient, there is scope for AVR-RD-02 to cut the cost of treating Gaucher disease.

Avrobio shared the early look at clinical data on AVR-RD-02 alongside updates about other assets. There is now more than three years of data on some Fabry patients treated with Avrobios lead asset, putting the company in a position to plot a path to accelerated approval. Avrobio plans to submit its briefing book to the FDA by the end of the year to align on an accelerated approval strategy.

The update also covered cystinosis candidate AVR-RD-04. The first patient to receive the candidate is off oral and eye drop cysteamine 12 months after receiving the gene therapy. The number of crystals in the patients skin are down 56%, leading Avrobio to posit they may have gained the ability to make their own functional cystinosin protein.

Link:
Avrobio tracks improvements in first patient treated with Gaucher gene therapy - FierceBiotech

COVID-19 Coronavirus molecule, March 24, 2020.

CDC | API | Gamma-Rapho via Getty Images

A team of CRISPR scientists at the New York Genome Center, New York University and Icahn School of Medicine at Mount Sinai say they have identified the genes that can protect human cells against Covid-19, a disease that has infected over 40 million and led to 1 million deaths worldwide. The discovery comes after an eight-month screen of all 20,000 genes in the human genome led by Dr. Neville Sanjana at the New York Genome Center. Leading virologist at Mount Sinai, Dr. Benjamin tenOever, developed a series of human lung cell models for the coronavirus screening to better understand immune responses to the disease and co-authored the study.

Their study, published online last month by Cell, will appear in the scientific peer-reviewed journal's Jan. 7 print issue.

The goal was two-fold: to identify the genes that make human cells more resistant to SARS-CoV-2 virus; and test existing drugs on the market that may help stop the spread of the disease.

The breakthrough comes at a time when drug makers such as Pfizer, Oxford-AstraZeneca and Moderna are fast-forwarding vaccine and therapeutics to treat Covid-19. On Friday, Pfizer and BioNTech requested emergency authorization from the FDA for their Covid vaccine that contains genetic material called messenger RNA, which scientists expect provokes the immune system to fight the virus.

In order to better understand the complex relationships between host and virus genetic dependencies, the team used a broad range of analytical and experimental methods to validate their results. This integrative approach included genome editing, single-cell sequencing, confocal imaging and computational analyses of gene expression and proteomic datasets.

After intensive research the scientists and doctors claim they have found 30 genes that block the virus from infecting human cells including RAB7A, a gene that seems to regulate the ACE-2 receptor that the virus binds to and uses to enter the cell. The spike protein's first contact with a human cell is through ACE-2 receptor.

"Our findings confirmed what scientists believe to be true about ACE-2 receptor's role in infection; it holds the key to unlocking the virus," said Dr. tenOever. "It also revealed the virus needs a toolbox of components to infect human cells. Everything must be in alignment for the virus to enter human cells."

The team discovered that the top-ranked genes those whose loss reduces viral infection substantially clustered into a handful of protein complexes, including vacuolar ATPases, Retromer, Commander, Arp2/3, and PI3K. Many of these protein complexes are involved in trafficking proteins to and from the cell membrane.

"We were very pleased to see multiple genes within the same family as top-ranked hits in our genome-wide screen. This gave us a high degree of confidence that these protein families were crucial to the virus lifecycle, either for getting into human cells or successful viral replication," said Dr. Zharko Daniloski, a postdoctoral fellow in the Sanjana Lab and co-first author of the study.

Using proteomic data, they found that several of the top-ranked host genes directly interact with the virus's own proteins, highlighting their central role in the viral lifecycle. The team also analyzed common host genes required for other viral pathogens, such as Zika or H1N1 pandemic influenza.

The research team also identified drugs that are currently on the market for different diseases that they claim block the entry of Covid-19 into human cells by increasing cellular cholesterol. In particular, they found three drugs currently on the market were more than 100-fold more effective in stopping viral entry in human lung cells:

The other five drugs that were tested called PIK-111, Compound 19, SAR 405, Autophinib, ALLN -- are used in research but are not yet branded and used in clinical trials for existing diseases.

Our findings confirmed what scientists believe to be true about ACE-2 receptor's role in infection; it holds the key to unlocking the virus.

Their findings offer insight into novel therapies that may be effective in treating Covid-19 and reveal the underlying molecular targets of those therapies.

The bioengineers in New York were working on other projects with gene-editing technology from CRISPR but quickly pivoted to studying the coronavirus when it swept through the metropolitan area last March. "Seeing the tragic impact of Covid-19 here in New York and across the world, we felt that we could use the high-throughput CRISPR gene editing tools that we have applied to other diseases to understand what are the key human genes required by the SARS-CoV-2 virus," said Dr. Sanjana.

Dr. Neville Sanjana and his team at the New York Genome Center used CRISPR to identify the genes that can protect human cells against Covid-19.

New York Genome Center

As he explained, "current treatments for SARS-CoV-2 infection currently go after the virus itself, but this study offers a better understanding of how host genes influence viral entry and will enable new avenues for therapeutic discovery."

Previously, Dr. Sanjana has applied genome-wide CRISPR screens to identify the genetic drivers of diverse diseases, including drug resistance in melanoma, immunotherapy failure, lung cancer metastasis, innate immunity, inborn metabolic disorders and muscular dystrophy.

"The hope is that the data from this study which pinpoints required genes for SARS-CoV-2 infection could in the future work be combined with human genome sequencing data to identify individuals that might be either more susceptible or more resistant to COVID-19," Dr. Sanjana said.

The New York team is not the first to use CRISPR gene editing techniques to fight Covid-19. Other bioengineering groups at MIT and Stanford have been using CRISPR to develop ways to fight the SARS-CoV-2 and develop diagnostic tools for Covid-19.

The potential for using CRISPR to eliminate viruses has already generated some enthusiasm in the research community. Last year, for example, Excision BioTherapeuticslicenseda technology from Temple University that uses CRISPR, combined with antiretroviral therapy, to eliminate HIV, the virus that causes AIDS.

Read the original post:
Gene experts claim they identified human genes that can protect against Covid-19 - CNBC

Vivet Therapeutics and Pfizer Inc. Announce FDA Authorization to Proceed with GATEWAY, the Phase 1/2 Study for VTX-801, Vivets Investigational Gene Therapy for Wilson Disease

PARIS, France and NEW YORK, N.Y.November 18, 2020 Vivet Therapeutics (Vivet), a privately held gene therapy biotech company dedicated to developing treatments for inherited liver disorders with high unmet medical need, and Pfizer Inc. (NYSE: PFE) announced today that the U.S. Food and Drug Administration (FDA) has cleared Vivets Investigational New Drug (IND) application for the GATEWAY study, a Phase 1/2 clinical trial evaluating Vivets proprietary, investigational gene therapy vector, VTX-801, for the potential treatment of Wilson disease (WD), a rare and potentially life-threatening liver disorder. The trial is expected to commence in early 2021.

We are pleased to announce Vivets first IND clearance by the FDA, which is for our GATEWAY Phase 1/2 study for VTX-801, said Jean-Philippe Combal, CEO and Co-Founder of Vivet. This is a very important milestone for the Wilson disease community for whom VTX-801 could bring significant potential therapeutic benefit. VTX-801 aims to restore copper homeostasis and the GATEWAY trial will measure relevant biomarkers to evaluate physiological restoration of copper elimination and transport in patients. We look forward to advancing VTX-801 into the clinic in early 2021.

VTX-801 is a novel, investigational rAAV-based gene therapy vector designed to deliver a miniaturized ATP7B transgene encoding, a functional protein that has been shown to restore copper homeostasis, reverse liver pathology and reduce copper accumulation in the brain of a mouse model of Wilson disease. VTX-801s rAAV serotype was selected based on its demonstrated tropism for transducing human liver cells.

In March 2019, the companies announced that Pfizer had acquired a minority equity interest in Vivet and secured an exclusive option to acquire all outstanding shares. In September 2020, Vivet and Pfizer announced the signing of an agreement for the manufacture by Pfizer of the VTX-801 vector for the GATEWAY study.

The FDA clearance of Vivets IND marks an important milestone for the VTX-801 program, which we believe has the potential to become a transformational therapy for people with Wilson disease, said Seng Cheng, Chief Scientific Officer, Rare Disease Research Unit, Pfizer. Pfizer has begun manufacturing clinical material for the GATEWAY study and look forward to the studys commencement.

This IND is a recognition of the expertise of Vivets research team led by our CSO and Co-Founder, Dr. Gloria Gonzlez-Aseguinolaza, research collaborations, notably with la Fundacin para la Investigacin Mdica Aplicada (FIMA), and experienced development team. We believe that our global development expertise, together with our collaboration with Pfizer, places us in a strong position to rapidly execute and bring this potentially transformational therapy to patients with high unmet medical needs, added Jean-Philippe Combal.

About GATEWAY - Phase 1/2 Clinical Trial of VTX-801 in Wilson disease

The GATEWAY trial is a multi-center, non-randomized, open-label, Phase 1/2 clinical trial designed to assess the safety, tolerability and pharmacological activity of a single intravenous infusion of VTX-801 in adult patients with Wilson disease, prior to and following background WD therapy withdrawal.

Six leading centers in the United States and Europe are expected to participate in the GATEWAY Phase 1/2 trial. The trial is expected to enroll up to sixteen adult patients with Wilson disease and will evaluate up to three doses of VTX-801. Patients will participate in a pre-dosing observational period and will be administered a prophylactic steroid regimen.

The primary endpoint of the GATEWAY trial is to assess the safety and tolerability of VTX-801 at 52 weeks after a single infusion. Additional endpoints include changes in disease-related biomarkers, including free serum copper and serum ceruloplasmin activity, as well as radiocopper-related parameters and VTX-801 responder status to allow standard-of-care withdrawal.

Vivet Therapeutics expects to enroll the first patient in early 2021.

More details on:

https://clinicaltrials.gov/ct2/show/NCT04537377?term=VIVET&draw=2&rank=1

About Vivet Therapeutics

Vivet Therapeutics is an emerging biotechnology company developing novel gene therapy treatments for rare, inherited metabolic diseases.

Vivet is building a diversified gene therapy pipeline based on novel recombinant adeno-associated virus (rAAV) technologies developed through its partnerships with, and exclusive licenses from, the Fundacin para la Investigacin Mdica Aplicada (FIMA), a not-for-profit foundation at the Centro de Investigacin Medica Aplicada (CIMA), University of Navarra based in Pamplona, Spain.

Vivets lead program, VTX-801, is a novel investigational gene therapy for Wilson disease which has been granted Orphan Drug Designation (ODD) by the Food and Drug Administration (FDA) and the European Commission (EC). This rare genetic disorder is caused by mutations in the gene encoding the ATP7B protein, which reduces the ability of the liver and other tissues to regulate copper levels causing severe hepatic damages, neurologic symptoms and potentially death.

Vivets second gene therapy product, VTX-803 for PFIC3, received US and European Orphan Drug Designation in May 2020.

Vivet is supported by international life science investors including Novartis Venture Fund, Roche Venture Fund, HealthCap, Pfizer Inc., Columbus Venture Partners, Ysios Capital, Kurma Partners and Idinvest Partners.

Please visit us on http://www.vivet-therapeutics.com and follow us on Twitter at @Vivet_tx and LinkedIn.

About Pfizer: Breakthroughs That Change Patients Lives

At Pfizer, we apply science and our global resources to bring therapies to people that extend and significantly improve their lives. We strive to set the standard for quality, safety and value in the discovery, development and manufacture of health care products, including innovative medicines and vaccines. Every day, Pfizer colleagues work across developed and emerging markets to advance wellness, prevention, treatments and cures that challenge the most feared diseases of our time. Consistent with our responsibility as one of the world's premier innovative biopharmaceutical companies, we collaborate with health care providers, governments and local communities to support and expand access to reliable, affordable health care around the world. For more than 170 years, we have worked to make a difference for all who rely on us. We routinely post information that may be important to investors on our website at http://www.Pfizer.com. In addition, to learn more, please visit us on http://www.Pfizer.com and follow us on Twitter at @Pfizer and @Pfizer News, LinkedIn, YouTube and like us on Facebook at Facebook.com/Pfizer.

Pfizer Disclosure Notice

The information contained in this release is as of November 18, 2020. Pfizer assumes no obligation to update forward-looking statements contained in this release as the result of new information or future events or developments.

This release contains forward-looking information about Vivet Therapeutics (Vivet) investigational gene therapy, VTX-801, and Pfizers collaboration with Vivet on the development of VTX-801, including their potential benefits, that involves substantial risks and uncertainties that could cause actual results to differ materially from those expressed or implied by such statements. Risks and uncertainties include, among other things, risks related to the ability to realize the anticipated benefits of the collaboration, including the possibility that the expected benefits from the collaboration will not be realized or will not be realized in the expected time; the uncertainties inherent in research and development, including the ability to meet anticipated clinical endpoints, commencement and/or completion dates for our clinical trials, regulatory submission dates, regulatory approval dates and/or launch dates, as well as the possibility of unfavorable new clinical data and further analyses of existing clinical data; the risk that clinical trial data are subject to differing interpretations and assessments by regulatory authorities;whether regulatory authorities will be satisfied with the design of and results from the clinical studies; whether and when any applications may be filed in any jurisdiction for VTX-801; whether and when any such applications may be approved by regulatory authorities, which will depend on myriad factors, including making a determination as to whether the products benefits outweigh its known risks and determination of the products efficacy and, if approved, whether VTX-801 will be commercially successful; decisions by regulatory authorities impacting labeling, manufacturing processes, safety and/or other matters that could affect the availability or commercial potential of VTX-801; uncertainties regarding the impact of COVID-19 on Pfizers business, operations and financial results;and competitive developments.

A further description of risks and uncertainties can be found in Pfizers Annual Report on Form 10-K for the fiscal year ended December 31, 2019 and in its subsequent reports on Form 10-Q, including in the sections thereof captioned Risk Factors and Forward-Looking Information and Factors That May Affect Future Results, as well as in its subsequent reports on Form 8-K, all of which are filed with the U.S. Securities and Exchange Commission and available atwww.sec.govandwww.pfizer.com.

Continued here:
Vivet Therapeutics and Pfizer Inc. Announce FDA Authorization to Proceed with GATEWAY, the Phase 1/2 Study for VTX-801, Vivet's Investigational Gene...

Nov. 16, 2020 12:30 UTC

- Highly innovative genome editing technology platform accelerates and broadens ElevateBios cell and gene therapy enabling technologies

- LifeEDIT Therapeutics to develop its own pipeline of potentially life-transforming therapeutics

- LifeEDIT Therapeutics to leverage its novel gene editing platform with strategic partners including ElevateBio portfolio companies

CAMBRIDGE, Mass. & RESEARCH TRIANGLE PARK, N.C.--(BUSINESS WIRE)-- ElevateBio, a Cambridge-based cell and gene therapy holding company, and AgBiome, a leader in developing innovative products from the Earth's microbial communities, today announced that LifeEDIT Therapeutics has joined ElevateBios growing portfolio of therapeutic, technology and manufacturing companies. LifeEDIT Therapeutics combines a highly innovative genome editing platform, derived from AgBiomes massive proprietary microbial library, with ElevateBios proven expertise in the discovery and development of new cell and gene therapies. LifeEDIT will continue to develop internal cell and gene therapies while further strengthening its platform of diverse genome-editing enzymes and provide gene editing expertise to strategic partners including ElevateBio portfolio companies. AgBiome retains rights for gene editing in agriculture, animal health, and diagnostics.

Genome editing technologies have revolutionized the way we develop cell and gene therapies and regenerative medicines, said Mitchell Finer, Ph.D., President, ElevateBio BaseCamp, and newly appointed Chief Executive Officer, LifeEDIT Therapeutics. However, in order to realize the promise of, and democratize, these highly innovative therapeutic approaches, the field needs to access novel RNA-guided nucleases and base editors that offer greater specificity and broader genome coverage, which LifeEDIT can provide. LifeEDITs genome editing platform is one of the most versatile in the field and was the natural fit as we continue to build a world leading cell and gene therapy offering.

Members of ElevateBio will join the newly formed LifeEDIT Therapeutics management team, which will continue to benefit from its existing visionary scientific leadership and research team. The combined executive team will include:

Over the last 18 months we have built a truly unique platform of numerous RNA-guided nucleases with diverse PAM requirements, for which weve been able to show functional activity, said Tedd Elich, Ph.D., Chief Scientific Officer, LifeEDIT Therapeutics. The wide range of gene editing enzymes across our platform increases our ability to target any genomic sequence of interest and will allow us to tackle some of the most challenging diseases, bringing desperately needed, potentially curative, therapies to patients in need.

"AgBiome's GENESISTM platform is built on our microbial collection, their complete genome sequences, and our industry-best data science platform to identify new useful functions, said Eric Ward Co-Chief Executive Officer, AgBiome. This unique resource formed the basis for the many genome editing technologies that are now part of LifeEDIT Therapeutics. We look forward to continuing to collaborate with the LifeEDIT team as they build a world-class pipeline of clinical candidates and bring a broad array of genome editing technologies to innovators across the biotechnology industry."

About Genome Editing and LifeEDIT Therapeutics Platform

Genome editing technologies have revolutionized the way cell and gene therapies and regenerative medicines are discovered and developed by allowing genetic material to be removed, added, or altered at specific locations in the genome. While these technologies are in widespread use experimentally, enzymes that offer broader coverage and greater specificity are needed for creating novel cell and gene therapies.

To meet the need for better genome editing approaches, LifeEDIT Therapeutics has built one of the worlds largest and most diverse arrays of novel RNA-guided nucleases (RGNs) and base editors that are active in mammalian cells. These RGNs were developed using AgBiomes proprietary collection of more than 90,000 microbes and their complete genomes. LifeEDIT Therapeutics is investigating these proprietary RGNs, which are sourced exclusively from non-pathogenic organisms, to develop new gene editing tools with higher fidelity, novel functionality, reduced immune response risk, and easier delivery. LifeEDIT Therapeutics nuclease collection also has a broad range of Protospacer Adjacent Motifs (PAMs) short sequences that must follow the targeted DNA sequence in order for the enzyme to make cuts that offer unprecedented access to genomic loci of interest. The LifeEDIT Therapeutics RGNs offer flexible editing options which encompass knock-out and knock-in capabilities, transcriptional regulation, and base editing when coupled with its proprietary deaminases.

LifeEDIT Therapeutics next generation editing systems will propel the development of novel human therapeutics by enabling ex vivo engineering for cell therapies and regenerative medicines and in vivo delivery of gene therapies. In addition to developing its own pipeline of cell and gene therapies, LifeEDIT Therapeutics will continue to build its platform of novel nucleases, provide gene editing expertise to strategic partners and ElevateBios portfolio companies, and form other third-party partnerships to discover and develop new therapies.

About ElevateBio

ElevateBio, LLC, is a Cambridge-based creator and operator of a portfolio of innovative cell and gene therapy companies. It begins with an environment where scientific inventors can transform their visions for cell and gene therapies into reality for patients with devastating and life-threatening diseases. Working with leading academic researchers, medical centers, and corporate partners, ElevateBios team of scientists, drug developers, and company builders are creating a portfolio of therapeutics companies that are changing the face of cell and gene therapy and regenerative medicine. Core to ElevateBios vision is BaseCamp, a centralized state-of-the-art innovation and manufacturing center, providing fully integrated capabilities, including basic and translational research, process development, clinical development, cGMP manufacturing, and regulatory affairs across multiple cell and gene therapy and regenerative medicine technology platforms. ElevateBio portfolio companies, as well as select strategic partners, are supported by ElevateBio BaseCamp in the advancement of novel cell and gene therapies.

ElevateBios investors include F2 Ventures, MPM Capital, EcoR1 Capital, Redmile Group, Samsara BioCapital, The Invus Group, Emerson Collective, Surveyor Capital (A Citadel company), EDBI, and Vertex Ventures.

ElevateBio is headquartered in Cambridge, Mass, with ElevateBio BaseCamp located in Waltham, Mass. For more information, please visit http://www.elevate.bio.

About AgBiome

AgBiome partners with the microbial world to improve our planet. AgBiome discovers and develops innovative biological and trait products for crop protection. The proprietary GENESIS discovery platform efficiently captures diverse, unique microbes for agriculturally relevant applications, and screens them with industry-best assays for insect, disease, and nematode control. Through its commercial subsidiary, AgBiome develops and sells proprietary crop protection solutions. The first of these, Howler, is a revolutionary fungicide for disease control in a broad variety of crops. AgBiome and Genective recently formed a strategic partnership to establish a new leader in insect traits, a market with over $5 billion in annual opportunities. AgBiome has a global R&D collaboration with Elanco Animal Health Incorporated (NYSE: ELAN), to develop nutritional health products for swine. AgBiomes investors include Polaris Partners, ARCH Venture Partners, Fidelity Investments Inc., UTIMCO, Pontifax AgTech, Innotech Advisors, Syngenta Ventures, Leaps by Bayer, and Novozymes. For more information, visit http://agbiome.com.

View source version on businesswire.com: https://www.businesswire.com/news/home/20201116005105/en/

Original post:
ElevateBio and AgBiome Announce LifeEDIT Will Join ElevateBio's Portfolio of Innovative Cell and Gene Therapy Companies - BioSpace

MarketsandResearch.biz presents Global Cell and Gene Therapy Market 2020 by Company, Regions, Type and Application, Forecast to 2025 which shows the most recent industry chain structure and complete analysis of the market. The report offers detailed information on enterprises on a global and regional level through an all-inclusive analysis and insights into developments affecting businesses. The report covers the market landscape and its growth prospects over the coming years. Leading companies effective in this market are discussed further. The report calculates the market size and considers the revenue generated from the sales of Cell and Gene Therapy globally. The research accommodates an entire overview of the market, including the market share, and the projection of this global market, within a specific interval of time.

The report contains critical information on the market which will assist the industry players in making informed business move. The report is segmented by application/ end-user, product type, and geologies. This report will help you to make informed decisions, understand opportunities, plan new projects, analyze drivers and restraints, and give you a vision of the industry forecast (2020-2025). The report further explains the competitive backdrop of key players in the market as well as their product portfolio and business strategies. It offers an investigation of the global Cell and Gene Therapy industry in terms of consumption and production.

DOWNLOAD FREE SAMPLE REPORT: https://www.marketsandresearch.biz/sample-request/110107

NOTE: Our report highlights the major issues and hazards that companies might come across due to the unprecedented outbreak of COVID-19.

Market Status:

The market report provides the major growth factors and limitations that notably affect market growth. The report studies the data about the past and present status of the global Cell and Gene Therapy market globally. The upcoming economic fluctuations related to the current market growth pattern of the market are investigated. Highlights of the segmentation study include price, revenue, sales, sales growth rate, and market share by product.

The market competition by top manufacturers/key player profiled: Amgen Inc., Novartis AG, Fibrocell Science, Inc., bluebird bio, Inc., Kolon TissueGene, Inc., Dendreon Pharmaceuticals LLC., Organogenesis Holdings Inc., Kite Pharma, Inc., Human Stem Cells Institute, Orchard Therapeutics plc., Spark Therapeutics, Inc., Pfizer, Inc., Vericel Corporation, Sibiono GeneTech Co. Ltd.,, RENOVA THERAPEUTICS, ViroMed Co., Ltd., Shanghai Sunway Biotech Co., Ltd.,

The report conjointly categorizes the market into main product kind: Rare Diseases, Oncology, Hematology, Cardiovascular, Ophthalmology, Neurology, Other Therapeutic Classes

The report splits the market into main applications: Pharmaceutical and Biotechnology Companies, Research and Academic Institutions, Contract Research Organizations (CROs), Hospital, Others

The report offers an in-depth assessment of the growth and other aspects of the market in important regions, including: North America (United States, Canada and Mexico), Europe (Germany, France, United Kingdom, Russia and Italy), Asia-Pacific (China, Japan, Korea, India, Southeast Asia and Australia), South America (Brazil, Argentina), Middle East & Africa (Saudi Arabia, UAE, Egypt and South Africa)

The conclusion contains the evaluation of the global Cell and Gene Therapy market through multiple classifications and provides thorough information about the upstream raw materials, downstream buyers, and distribution channels established by the various competitors. More importantly, a study of recent market trends, drivers, challenges, and opportunities shaping the profitability graph of the industry are presented further in the report.

ACCESS FULL REPORT: https://www.marketsandresearch.biz/report/110107/global-cell-and-gene-therapy-market-2020-by-company-regions-type-and-application-forecast-to-2025

Key Pointers:

Customization of the Report:

This report can be customized to meet the clients requirements. Please connect with our sales team ([emailprotected]), who will ensure that you get a report that suits your needs. You can also get in touch with our executives on +1-201-465-4211 to share your research requirements.

Contact UsMark StoneHead of Business DevelopmentPhone: +1-201-465-4211Email: [emailprotected]Web: http://www.marketsandresearch.biz

See the article here:
Global Cell and Gene Therapy Market 2020 Key Drivers and Challenges, Opportunities and Forecast Insights by 2025 - KYT24